Systems and methods for identifying copy number alterations
The method of moments is used to solve nonlinear equations for tumor purity and ploidy, addressing the instability of current methods in copy number change identification, resulting in precise and efficient biomarker estimation for cancer analysis and treatment.
Patent Information
- Application Number
- JP2024526000
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-03
- Filing Date
- 2022-11-01
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for identifying copy number changes in cancer genomes are inaccurate and unstable due to the indistinguishability of tumor purity and tumor ploidy, leading to unreliable biomarker values and inefficient computation.
A method using the method of moments to solve a system of nonlinear equations for determining tumor purity and ploidy, allowing precise estimation of copy numbers and minor allele frequencies through statistical moments of sequencing depth signals.
Provides high precision, accuracy, and computational efficiency in determining copy number changes, enabling stable and reliable biomarker values for cancer diagnosis and treatment.
Smart Images

Figure 2024542067000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 275,154, filed November 3, 2021, the contents of which are incorporated by reference herein in their entirety.
[0002] The present disclosure relates to methods and systems for identifying genomic copy number alterations and uses thereof. [Background technology]
[0003] Cancer genomes are characterized by important somatic alterations associated with cancer development. These alterations can range from single base changes to copy number alterations (CNAs) of large chromosomal fragments, including both deletions and duplications, ranging in size from several kilobases to entire chromosomes. Identification of somatic CNAs associated with specific cancer genomes is an important area in cancer genome analysis. Various studies have shown that CNAs of specific genes are important predictive and prognostic biomarkers in precision medicine, for example, PTEN loss has been shown to be significantly associated with disease-specific mortality in multivariate analysis. While only a small percentage of somatic mutations, termed driver mutations, contribute to the cancer phenotype, most somatic mutations are random, i.e., these passenger mutations do not contribute to the disease. Somatic CNAs that occur during an individual's lifetime are a major contributor to the development of cancer, especially solid tumors.
[0004] High-throughput next-generation sequencing (NGS) and other technologies have been introduced to measure CNAs. For example, NGS has been shown to identify CNAs as deviations from the expected number of reads aligned to intervals of the reference genome, and depending on the sequencing depth and technology, CNAs can be measured down to single-nucleotide resolution. In parallel with technological developments, numerous computational methods have been developed to identify CNAs in single samples. However, tumor purity and tumor ploidy substantially affect NGS analysis and alter the interpretation of results.
[0005] Currently, the estimation of tumor purity and tumor ploidy relies heavily on statistically distinguishing tumor cells from normal cells in a sample by leveraging coverage depth and minor allele frequency (MAF) information. The most important problem with this approach is that of discriminability, where different combinations of tumor purity and tumor ploidy can often equally well explain the observed data, resulting in inconsistent (i.e., unstable, inaccurate) estimates.
[0006] Therefore, there is a need for improved methods and systems for identifying copy number alterations. In particular, there is a need for efficient computational methods with improved precision and accuracy in determining copy number alterations. Such methods would be beneficial for cancer genomic analysis, diagnosis, and treatment. Summary of the Invention
[0007] Provided herein are methods, including computer-implemented methods, for identifying copy number changes with high accuracy and precision. Further provided herein are the uses of such methods for various applications, including cancer genome analysis, diagnosis, and treatment. Previous methods for estimating copy number were based on, for example, log ratio coverage data and allele frequencies for thousands of heterozygous single nucleotide polymorphisms (SNPs). This experimental data is segmented and modeled to estimate overall tumor purity and tumor ploidy, and copy number and minor allele frequency (MAF) per segment are determined. Then, the log ratio and MAF data are fitted by a statistical copy number model that predicts genome-wide copy number for each segment. Due to over-parameterization, traditional methods for determining copy number are typically not distinguishable, i.e., experimental data can be described by two or more sets of statistical model parameter values (e.g., tumor purity, tumor ploidy, and segment copy number), which leads to unstable prediction of copy number.
[0008] The disclosed method is based on the method of moments to generate a system of nonlinear equations that can be solved to determine the specific values for tumor purity and tumor ploidy, which can then be used to determine segment copy number and minor allele frequency (MAF).The method has higher precision, accuracy and computational efficiency compared to previous methods due to the stability and reliability of copy number estimation, thus providing an advance over previous methods for estimating copy number and identifying copy number changes.The present specification also provides an exemplary computer-readable storage medium and electronic device for implementing such method.
[0009] In one aspect, the disclosure provides a method for determining copy number of a target genome segment in a genome of a sample from a subject, comprising providing a plurality of nucleic acid molecules from the sample; ligating one or more adaptors onto one or more nucleic acid molecules from the plurality of nucleic acid molecules; amplifying one or more ligated nucleic acid molecules to form a plurality of nucleic acid molecules; capturing amplified nucleic acid molecules from the amplified nucleic acid molecules; sequencing the captured nucleic acid molecules using a sequencer (e.g., a next generation sequencer or a massively parallel sequencer) to obtain a plurality of sequence reads representative of the captured nucleic acid molecules, wherein one or more of the plurality of sequence reads overlap with a plurality of genome segments in the genome of the sample; and sequencing the plurality of sequence reads using one or more processors of a computer system to obtain a plurality of sequence reads representative of the captured nucleic acid molecules, wherein one or more of the plurality of sequence reads overlap with a plurality of genome segments in the genome of the sample. The present invention provides a method for determining a plurality of sequencing depth signals for a target genome segment, the plurality of genome segments comprising ...
[0010] In some embodiments, the subject is suspected of having or determined to have cancer. In some embodiments, the method further comprises obtaining a tissue sample from the subject. In some embodiments, the sample comprises a tissue biopsy sample, a liquid biopsy sample, or a normal control. In some embodiments, the sample is a liquid biopsy sample and comprises blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva. In some embodiments, the sample is a liquid biopsy sample and comprises circulating tumor cells (CTCs). In some embodiments, the sample is a liquid biopsy sample and comprises cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof. In some embodiments, the plurality of nucleic acid molecules comprises a mixture of tumor nucleic acid molecules and non-tumor nucleic acid molecules. In some embodiments, the tumor nucleic acid molecules are derived from a tumor portion of a heterogeneous tissue biopsy sample, and the non-tumor nucleic acid molecules are derived from a normal portion of a heterogeneous tissue biopsy sample. In some embodiments, the sample comprises a liquid biopsy sample, the tumor nucleic acid molecule is derived from a circulating tumor DNA (ctDNA) fraction of the liquid biopsy sample, and the non-tumor nucleic acid molecule is derived from a non-tumor cell-free DNA (cfDNA) fraction of the liquid biopsy sample. In some embodiments, the one or more adaptors comprise an amplification primer, a flow cell adaptor sequence, a substrate adaptor sequence, or a sample index sequence. In some embodiments, the captured nucleic acid molecule is captured from the amplified nucleic acid molecule by hybridization to one or more bait molecules. In some embodiments, the one or more bait molecules comprise one or more nucleic acid molecules, each nucleic acid molecule comprising a region complementary to a region of the captured nucleic acid molecule. In some embodiments, amplifying the nucleic acid molecule comprises performing a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique. In some embodiments, the sequencing comprises using a massively parallel sequencing (MPS) technique, a whole genome sequencing (WGS), a whole exome sequencing, a targeted sequencing, a direct sequencing, or a Sanger sequencing technique. In some embodiments, the sequencing comprises massively parallel sequencing, and the massively parallel sequencing technology comprises next generation sequencing (NGS). In some embodiments, the sequencing comprises a next generation sequencer.In some embodiments, the method further includes generating, by the one or more processors, a report that includes the determined tumor purity, tumor ploidy, copy number of the target genome segment, genomic profile for the sample, or any combination thereof. In some embodiments, the method further includes transmitting the report to a health care provider. In some embodiments, the report is transmitted over a computer network or a peer-to-peer connection.
[0011] In another aspect, the present disclosure provides a method for determining the copy number of a target genome segment in a genome of a sample from a subject, comprising: using one or more processors of a computer to obtain a plurality of sequencing depth signals for a plurality of genome segments in the genome of the sample, the sequencing depth signals being associated with the number of sequence reads aligned to a locus in the genome segment, the plurality of genome segments including the target genome segment; using one or more processors to determine a first statistical moment, a second statistical moment, and a third statistical moment for the plurality of genome segments from the plurality of sequencing depth signals; using one or more processors to determine a tumor purity and a tumor ploidy for the sample from the first statistical moment, the second statistical moment, and the third statistical moment; and using the plurality of sequencing depth signals, the tumor purity, and the tumor ploidy for the target genome segment to determine the copy number of the target genome segment in the genome of the sample. In some embodiments, the method further comprises generating a genomic profile for the sample based on the determined copy number by the computer system.
[0012] In some embodiments, the multiple sequencing depth signals of the sample are normalized using a process matched control. In some embodiments, the method further comprises segmenting the genome to generate multiple genome segments. In some embodiments, the genome is segmented based on the sequencing depth signals. In some embodiments, the genome is segmented using a circular binary segmentation (CBS) method. In some embodiments, determining tumor purity and tumor ploidy comprises solving a set of nonlinear equations. In some embodiments, the method further comprises sequencing nucleic acid of the sample to generate sequence reads derived from the sample. In some embodiments, the sequence reads derived from the sample are generated by sequencing nucleic acid of the sample using massively parallel sequencing. In some embodiments, the sample is from an individual having lung cancer, colon cancer, ovarian cancer, breast cancer, prostate cancer, and / or pancreatic cancer. In some embodiments, the target genome segment comprises a gene of interest. In some embodiments, the gene of interest is a phosphatase and tensin homolog (PTEN) gene, a breast cancer 1 (BRCA1) gene, or a breast cancer 2 (BRCA2) gene. In some embodiments, the gene of interest is an oncogenic or cell transforming gene. In some embodiments, the oncogenic or cell transforming gene comprises an MLL fusion gene, BCR-ABL, TEL-AML I, EWS-FL11, TLS-FUS, PAX3-FKHR, Bcl-2, AML1-ETO, AML1-MTG8, Ras, Fos PDGF, RET, APC, NF-1, Rb, p53, or MDM2. In some embodiments, the gene of interest is an overexpressed gene. In some embodiments, the overexpressed gene is a multidrug resistance gene, a cyclin gene, a beta-catenin gene, a telomerase gene; c-myc, n-myc, Bel-2, Erb-B1, Erb-B2, a mutated Ras gene, a mutated Mos gene, a mutated Raf gene, or a mutated Met gene. In some embodiments, the gene of interest is a tumor suppressor gene.In some embodiments, the tumor suppressor gene is p53, p21, RB1, WTI, NF1, VHL, APC, DAP kinase, p16, ARF, neurofibromin, or PTEN.
[0013] Also disclosed herein are methods for generating a dataset comprising the copy number of a target genome segment, wherein the copy number is determined by any of the methods described herein.
[0014] In some embodiments that may be combined with any of the preceding embodiments, the method further comprises determining a copy number alteration (CNA) of the target genome segment in the sample based on the determined copy number of the target genome segment. In some embodiments, determining the copy number alteration (CNA) of the genome segment in the sample comprises comparing the determined copy number of the target genome segment with a reference copy number of the target genome segment, and determining the copy number alteration (CNA) from the comparison by the presence of a difference between the determined copy number and the reference copy number of the target genome segment. In some embodiments, the method further comprises using the determined copy number alteration (CNA) as a biomarker in medical diagnosis and / or treatment. In some embodiments, the determined copy number is the copy number of a minor allele of the target genome segment.
[0015] In some embodiments that may be combined with any of the preceding embodiments, the method further comprises determining a copy number of a minor allele of the target genome segment and determining a loss of heterozygosity (LOH) of the minor allele of the target genome segment. In some embodiments, determining a loss of heterozygosity (LOH) of the minor allele of the target genome segment comprises: a) determining the presence of a determined copy number of the target genome segment greater than 0 and less than the sum of the determined tumor ploidy and 2; and b) based on the determined presence of a), determining a loss of heterozygosity (LOH) by the presence of any one of the following: a determined copy number of the target genome segment equal to 1, a determined copy number of the target genome segment equal to the determined minor allele copy number of the target genome segment, or a determined minor allele copy number of the target genome segment equal to 0. In some embodiments, the method further comprises calculating a genome-wide LOH (gLOH) percentage score as the sum of the lengths of the LOH segments divided by the length of the entire genome. In some embodiments, the methods further comprise using loss of heterozygosity (LOH) as a biomarker for homologous recombination deficiency (HRD).
[0016] In some embodiments that may be combined with any of the preceding embodiments, the method further comprises determining a tumor mutation burden (TMB) of the sample based on the determined copy number, the determined tumor purity, and / or the determined tumor ploidy. In some embodiments, determining the tumor mutation burden (TMB) comprises obtaining a plurality of genetic variants from a plurality of sequencing depth signals of the sample, inputting the plurality of genetic variants together with the determined copy number, the determined tumor purity, and / or the determined tumor ploidy into a model configured to determine and output a plurality of genetic variants that are of somatic origin, and determining the tumor mutation burden (TMB) of the sample by calculating the number of genetic variants of somatic origin per million base pairs of the genome based on the output of the model. In some embodiments, the method further comprises using the determined tumor mutation burden (TMB) as a biomarker in medical diagnosis and / or treatment.
[0017] In some embodiments that may be combined with any of the preceding embodiments, the method further comprises characterizing a mutational state of a genetic variant in the sample based on the determined copy number, the determined tumor purity, and / or the determined tumor ploidy. In some embodiments, characterizing the mutational state of the genetic variant comprises obtaining a genetic variant from a plurality of sequencing depth signals of the sample, obtaining a model configured to determine a mutational state of the genetic variant, and inputting the genetic variant together with the determined copy number, the determined tumor purity, and / or the determined tumor ploidy into the model, and characterizing the mutational state of the genetic variant by outputting the mutational state of the genetic variant. In some embodiments, the mutational state of the genetic variant is somatic or germline origin, homozygous or heterozygous state, subclonal state, or a combination thereof.
[0018] In some embodiments, the copy number-based genomic profile determined for the sample can be used to diagnose or confirm the diagnosis of a disease in a subject. In some embodiments, the disease is cancer. In some embodiments, the method may further include selecting an anti-cancer therapy to administer to the subject based on the genomic profile of the sample. In some embodiments, the method may further include determining an effective amount of the anti-cancer therapy to administer to the subject based on the genomic profile of the sample. In some embodiments, the method may further include administering an anti-cancer therapy to the subject. In some embodiments, the anti-cancer therapy comprises chemotherapy, radiation therapy, immunotherapy, targeted therapy, or surgery.In some embodiments, the cancer is B-cell cancer (multiple myeloma), melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, endometrial cancer, oral cavity cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, blood Tissue cancer, Adenocarcinoma, Inflammatory myofibroblastoma, Gastrointestinal stromal tumor (GIST), Colon cancer, Multiple myeloma (MM), Myelodysplastic syndrome (MDS), Myeloproliferative disorder (MPD), Acute lymphocytic leukemia (ALL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), Chronic lymphocytic leukemia (CLL), Polycythemia Vera, Hodgkin's lymphoma, Non-Hodgkin's lymphoma (NHL), Soft tissue sarcoma, Fibrosarcoma, Myxosarcoma, Lipoma Liposarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharynx Cephaloma, ependymoma, pineal cell tumor, glioblastoma, acoustic neuroblastoma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, essential thrombocythemia, aplastic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familial eosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, or carcinoid tumor.
[0019] In another aspect, the present disclosure provides a method for selecting a treatment for an individual having cancer, the method comprising: determining copy number alterations (CNAs) in a sample from the individual, where the CNAs are determined according to the method of any one of the preceding embodiments; predicting the individual's response to one or more treatment options using the determined CNAs as biomarkers; and selecting a suitable treatment for the individual from the one or more treatment options based on the predicted response.
[0020] In another aspect, the disclosure provides a method for selecting a treatment for an individual having cancer, the method comprising: determining loss of heterozygosity (LOH) in a sample from the individual, where the LOH is determined according to the method of any one of the preceding embodiments; predicting the individual's response to one or more treatment options using the determined LOH as a biomarker; and selecting a suitable treatment for the individual from the one or more treatment options based on the predicted response.
[0021] In another aspect, the disclosure provides a method for selecting a treatment for an individual having cancer, the method comprising: determining a tumor mutational burden (TMB) in a sample from the individual, where the TMB is determined according to the method of any one of the preceding embodiments; predicting the individual's response to one or more treatment options using the determined TMB as a biomarker; and selecting a suitable treatment for the individual from the one or more treatment options based on the predicted response.
[0022] In yet another aspect, the disclosure provides a method for selecting a treatment for an individual having cancer, the method comprising: characterizing a mutation status of a genetic variant in a sample from the individual, wherein the mutation status is characterized according to the method of any one of the preceding embodiments; predicting the individual's response to one or more treatment options based on the characterized mutation status of the genetic variant; and selecting a suitable treatment for the individual from the one or more treatment options based on the predicted response.
[0023] In some embodiments, the mutation status of the genetic variant is the origin of the genetic variant, which is somatic or germline. In some embodiments, the method further comprises administering the selected treatment to the individual. In some embodiments, the cancer is B-cell cancer (multiple myeloma), melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, endometrial cancer, oral cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal cancer, osteosarcoma, chondrosarcoma, hematopoietic cancer, rhabdomyosarcoma ... Tissue cancer, Adenocarcinoma, Inflammatory myofibroblastoma, Gastrointestinal stromal tumor (GIST), Colon cancer, Multiple myeloma (MM), Myelodysplastic syndrome (MDS), Myeloproliferative disorder (MPD), Acute lymphocytic leukemia (ALL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), Chronic lymphocytic leukemia (CLL), Polycythemia Vera, Hodgkin's lymphoma, Non-Hodgkin's lymphoma (NHL), Soft tissue sarcoma, Fibrosarcoma, Myxosarcoma, Lipoma Liposarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharynx The tumor is selected from the group consisting of cranioma, ependymoma, pinealoma, glioblastoma, acoustic neuroblastoma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, essential thrombocythemia, aplastic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familial eosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, and carcinoid tumors. In some embodiments, the sample comprises a tissue biopsy sample, a liquid biopsy sample, or a normal control. In some embodiments, the sample is a liquid biopsy sample and comprises blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva. In some embodiments, the sample is a liquid biopsy sample and comprises circulating tumor cells (CTCs).In some embodiments, the sample is a liquid biopsy sample and includes cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof. In some embodiments, the selected treatment includes drug administration, chemotherapy, radiation therapy, immunotherapy, targeted therapy, gene therapy, surgery, or any combination thereof. In some embodiments, the selected treatment includes administering a checkpoint inhibitor to the individual. In some embodiments, the method further includes generating or updating a report from the process of selecting a treatment. In some embodiments, the method further includes transmitting the report to the individual or to a clinician. In some embodiments, the method further includes storing the report on a non-transitory computer readable storage medium. In some embodiments, the method further includes displaying the report on a computer display.
[0024] Further provided herein is a non-transitory computer-readable storage medium comprising one or more programs executed by one or more processors of a device, the one or more programs comprising instructions that, when executed by the one or more processors, cause the device to implement the method of any one of the preceding embodiments.
[0025] Further provided herein is a non-transitory computer readable storage medium comprising a report generated from performing the method of any one of the preceding embodiments.
[0026] The present disclosure also provides an electronic device including one or more processors, a memory, and one or more programs, the one or more programs including instructions that, when executed by the one or more processors, cause the device to perform the method of any one of the preceding embodiments. In some embodiments, the electronic device further includes one or more displays for presenting a report generated from performing the method of any one of the preceding embodiments.
[0027] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. In the event of a conflict between a term in this specification and a term in an incorporated reference, the term in this specification shall control. [Brief description of the drawings]
[0028] Various aspects of the disclosed methods, devices, and systems are set forth with particularity in the appended claims. A better understanding of the features and advantages of the disclosed methods, devices, and systems will be obtained by reference to the following detailed description of exemplary embodiments and the accompanying drawings.
[0029] [Figure 1] FIG. 1 shows a diagram of an exemplary process for determining the copy number of a target genome segment in a sample. [Diagram 2] FIG. 1 shows a diagram of another exemplary process for determining the copy number of a target genome segment and the minor allele copy number of the target genome segment in a sample. [Diagram 3] FIG. 1 shows a diagram of an exemplary process for determining copy number alterations (CNAs) of a target genomic segment in a sample. [Figure 4] FIG. 1 shows a diagram of an exemplary process for determining loss of heterozygosity (LOH) of a minor allele of a target genomic segment in a sample. [Diagram 5] FIG. 1 shows a diagram of an exemplary process for determining the tumor mutational burden (TMB) of a sample. [Figure 6] FIG. 1 shows a diagram of an exemplary process for characterizing the mutation status of genetic variants in a sample. [Figure 7] FIG. 1 shows a diagram of an exemplary process for selecting a treatment for an individual with cancer by using determined copy number alterations (CNAs) as biomarkers. [Figure 8]FIG. 1 shows a diagram of an exemplary process for selecting a treatment for an individual with cancer by using determined loss of heterozygosity (LOH) as a biomarker. [Figure 9] FIG. 1 shows a diagram of an exemplary process for selecting a treatment for an individual with cancer by using a determined tumor mutation burden (TMB) as a biomarker. [Figure 10] FIG. 1 shows a diagram of an exemplary process for selecting a treatment for an individual with cancer based on the characterized mutation status of a genetic variant. [Figure 11] 1 illustrates an exemplary computing system according to one embodiment of the present disclosure. [Figure 12] 1 illustrates an exemplary computer system or computer network in accordance with some examples of the systems described herein. [Figure 13] 1 shows a comparison of one embodiment of the method described herein with previous methods in estimating a genome-wide loss of heterozygosity (gLOH) score for an exemplary sample. [Figure 14] 1 shows a comparison of one embodiment of the method described herein with previous methods in estimating genome-wide loss of heterozygosity (gLOH) scores for another exemplary sample. [Figure 15] 1 shows a comparison of one embodiment of the method described herein with previous methods in estimating genome-wide loss of heterozygosity (gLOH) scores for yet another exemplary sample. [Figure 16] 1 shows a comparison of one embodiment of the method described herein with previous methods in estimating genome-wide loss of heterozygosity (gLOH) scores for yet another exemplary sample. [Figure 17] 1 shows a comparison of one embodiment of the method described herein with previous methods in estimating genome-wide loss of heterozygosity (gLOH) scores for yet another exemplary sample. [Figure 18]1 shows a comparison of one embodiment of the method described herein with previous methods in estimating genome-wide loss of heterozygosity (gLOH) scores for yet another exemplary sample. [Figure 19] 1 shows a comparison of one embodiment of the method described herein with previous methods in estimating genome-wide loss of heterozygosity (gLOH) scores for yet another exemplary sample. [Figure 20] 1 shows a comparison of one embodiment of the method described herein with previous methods in estimating genome-wide loss of heterozygosity (gLOH) scores for yet another exemplary sample. [Figure 21] 1 shows a comparison of one embodiment of the method described herein with previous methods in estimating genome-wide loss of heterozygosity (gLOH) scores for an exemplary sample in terms of percent coefficient variance (%CV). [Figure 22] Average estimated copy numbers of 3000-3500 for exemplary samples showing a comparison of one embodiment of the methods described herein with previous methods in predicting bait targets. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] Copy number alteration (CNA) estimation is particularly important in cancer genome analysis, since it is the basis for deriving complex biomarker values, such as genome-wide loss of heterozygosity (gLOH) scores. However, previous CNA models have many limitations. Most of the previous CNA models are not identifiable, and therefore the estimated tumor purity and copy number alteration are unstable (i.e., inaccurate), which may result in less reliable complex biomarker values. Furthermore, the computational methods of previous CNA models are not very efficient, and therefore their computational costs are higher.
[0031] Advantageously, the method disclosed herein has been found to provide superior accuracy, precision, and computational efficiency in determining copy number when compared to many of the previously used methods. The model described herein is devised by expressing population moments (e.g., expected values of the powers of the variables under consideration) as a function of the parameters of interest (e.g., tumor purity, tumor ploidy, copy number). These equations are set equal to the sample moments. The method estimates model parameters using the moment method, which is identifiable, to generate a nonlinear equation system that can be solved to determine the unique values of tumor purity and tumor ploidy, which can then be used to determine segment copy number and minor allele frequency (MAF), thus overcoming the problem of over-parameterization that conventional methods often face. Because the method can explicitly and uniquely estimate each model parameter, the estimated parameters, e.g., copy number, tumor purity, and tumor ploidy, are significantly more stable / precise (i.e., repeatable) and accurate (i.e., closer to the true value) than those obtained from other methods.
[0032] The following description is presented to enable those skilled in the art to make and use the various embodiments. Descriptions of specific devices, techniques, and applications are provided only as examples. Various modifications to the examples described herein will be readily apparent to those skilled in the art, and the general principles defined herein may be applied to other examples and applications without departing from the spirit and scope of the various embodiments. Thus, the various embodiments are not limited to the examples described and shown herein, but are to be accorded the scope consistent with the claims.
[0033] All references cited in this specification, including publications, patent applications, and patents, are herein incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and was set forth in its entirety herein.
[0034] definition Although the following description uses terms such as "first," "second," and the like to describe various elements, these elements should not be limited by these terms. These terms are only used to distinguish one element from another. For example, a first graphical representation can be referred to as a second graphical representation, and similarly, a second graphical representation can be referred to as a first graphical representation, without departing from the scope of the various embodiments described. Although the first graphical representation and the second graphical representation are both graphical representations, they are not the same graphical representation.
[0035] The terms used in the description of the various embodiments described herein are intended to describe particular embodiments only and are not intended to be limiting. As used in the description of the various embodiments described and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms unless the context clearly indicates otherwise. The term "and / or" as used herein will also be understood to refer to and include any possible combination of one or more of the associated listed items. It will be further understood that the terms "includes," "including," "comprises," and / or "comprising," as used herein, specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.
[0036] The term "if" is optionally interpreted to mean "when" or "upon" or "response to determining" or "response to detecting," depending on the context. Similarly, the phrases "if determined" or "if [stated condition or event] is detected" are optionally interpreted to mean "upon determining" or "in response to determining" or "upon detecting [stated condition or event]" or "in response to detecting [stated condition or event]," depending on the context.
[0037] The term "estimation" refers to a formal procedure for calculating values for one or more parameters of a population from observed sample data, with the resulting calculated parameter values being known as "estimators." For purposes of this disclosure, the terms "determining," "estimating," "identifying," "detecting," and "predicting" may be used interchangeably herein.
[0038] The term "sequencing depth signal" refers to the ratio of the sequencing depth of a sample to the sequencing depth of a control.
[0039] The term "process-matched control" refers to a control sample that is processed using the same sample preparation and sequencing pipeline as that used for the sample being analyzed, but the process-matched control sample is not derived from the subject from which the sample for analysis was derived. The process-matched control can be used, for example, to normalize the sequencing coverage of the sample. In some examples, the process-matched control can include, for example, a mixture of DNA from multiple HapMap cell lines.
[0040] The term "algorithm" refers to a procedure or set of instructions for solving a problem, especially by a computer. In some examples, algorithms can be used to develop "models," i.e., representations of certain parameters or conditions that can be used to make predictions. For purposes of this disclosure, the term "algorithm" may be used interchangeably with the term "method."
[0041] The term "statistical moment" or simply "moment" refers to a statistical parameter for describing an attribute or characteristic of a probability distribution. In some embodiments, the moment may be centered (i.e., with respect to the mean of the variable), which is also known as a "centered moment" or "central moment."
[0042] "Method of moments" refers to a method of estimation of a population parameter that begins by expressing the population moments (i.e., the expected values of the powers of the random variable under consideration) as a function of the parameter of interest.
[0043] The term "copy number alteration," "copy number aberration," or "CNA" refers to the gain or loss of a genomic segment in a tumor or cancerous cell that results in a variation from the copy number of that genomic segment in a normal cell, e.g., a variation from two copies in a normal human somatic cell.
[0044] The terms "genome-wide LOH percent," "genome-wide LOH," and "gLOH" refer to a measurement of LOH incidence across the genome (i.e., the percentage of LOH segments in the genome), calculated as the sum of the lengths of the LOH segments divided by the length of the total genome.
[0045] The terms "individual," "subject," and "patient," used interchangeably herein, refer to a human being, male or female, adult, child or infant, who is afflicted with a disease such as cancer.
[0046] The term "cancer" refers to a broad group of diverse diseases characterized by the uncontrolled growth of abnormal cells, and the term "tumor" refers to a mass of uncontrolled growth of abnormal cells. In some embodiments, the terms "cancer" and "tumor" may be used interchangeably, such as in a cancer sample or a tumor sample.
[0047] The terms "genetic variant", "variant" and "mutation" are used interchangeably herein to refer to a genomic sequence that differs from a reference sequence by one or more nucleotides due to substitution, insertion, deletion, or any other change. For example, a variant in a tumor sample refers to a genomic sequence in a tumor genome that differs from a reference sequence, e.g., from a normal control.
[0048] "Treatment" or "treatment" of a subject refers to any type of intervention or process performed on a subject, or the administration of an active agent to a subject, for the purpose of reversing, mitigating, ameliorating, inhibiting, slowing or preventing the onset, progression, occurrence, severity or recurrence of symptoms, complications, conditions or biochemical signs associated with a disease. In some embodiments, treatment can refer to prolonging survival as compared to expected survival if not receiving treatment.
[0049] The term "immunotherapy" refers to the treatment of a subject suffering from a disease or at risk of suffering from a disease or recurrence of a disease by methods involving inducing, enhancing, suppressing, or otherwise modifying the immune response.
[0050] The terms "personalized medicine," "individualized medicine," and "precision medicine" refer to the tailoring of medical procedures to each patient's individual characteristics based on the patient's unique molecular and / or genetic profile that predisposes or predisposes the patient to certain diseases and / or responds to certain treatments. Personalized medicine is improving the ability to predict which medical treatments are likely to be safe and effective for each patient, and which are likely not.
[0051] The terms "biomarker" and "marker" are used interchangeably herein to refer to a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or response to exposure or intervention, including therapeutic intervention.
[0052] The terms "computer," "processor," and "memory" all refer to electronic or other technological devices.
[0053] The term "display" or "displaying" means displaying on an electronic device.
[0054] The terms "computer readable medium" and "computer readable media," as used interchangeably herein, are strictly limited to tangible, physical objects that store information in a form readable by a computer. These terms exclude any wireless signals, wired download signals, and any other ephemeral signals.
[0055] Methods for determining copy numbers of genomic segments In one aspect, the disclosure provides a method for determining copy number of a target genome segment in a genome of a sample (e.g., a tumor sample), comprising providing a plurality of nucleic acid molecules from the sample; sequencing the plurality of nucleic acid molecules with a sequencer (such as a massively parallel sequencer) to obtain a plurality of sequence reads for the plurality of nucleic acid sequences; and using one or more processors of a computer system to obtain a plurality of sequencing depth signals for a plurality of genome segments in the genome of the sample, wherein the sequencing depth signals are related to a number of sequence reads aligned to loci in the genome segments, and The method includes: acquiring a sample including a target genome segment; determining, using one or more processors, a first statistical moment, a second statistical moment, and a third statistical moment for the plurality of genome segments from the plurality of sequencing depth signals; determining, using one or more processors, a tumor purity and a tumor ploidy for the sample from the first statistical moment, the second statistical moment, and the third statistical moment; and determining a copy number of the genome segment in the genome of the sample using the plurality of sequencing depth signals, the tumor purity, and the tumor ploidy for the target genome segment. In some examples, the method may further include generating, by the computer system, a genomic profile based on the determined copy number.
[0056] In another aspect, a computer-implemented method for determining the copy number of a target genome segment in a genome of a sample (e.g., a tumor sample) is provided herein, comprising: using one or more processors of a computer to obtain a plurality of sequencing depth signals for a plurality of genome segments in the genome of the sample, the sequencing depth signals being associated with the number of sequence reads aligned to a locus in the genome segment, the plurality of genome segments including the target genome segment; using one or more processors to determine a first statistical moment, a second statistical moment, and a third statistical moment for the plurality of genome segments from the plurality of sequencing depth signals; using one or more processors to determine a tumor purity and a tumor ploidy for the sample from the first statistical moment, the second statistical moment, and the third statistical moment; and using the plurality of sequencing depth signals, the tumor purity, and the tumor ploidy for the target genome segment to determine the copy number of the target genome segment in the genome of the sample. In some examples, the computer-implemented method may further comprise generating a genome profile based on the determined copy number by the computer system.
[0057] Figure 1 shows a diagram of such an exemplary process 100. In step 102 of Figure 1, multiple sequencing depth signals are obtained for multiple genome segments (i.e., subsegments of a genome) in a sample (e.g., a tumor sample), where the multiple genome segments may include a target genome segment. As described in more detail below, the sequencing depth signal is related to the number of sequence reads aligned to loci in the genome segment.
[0058] In step 104 of FIG. 1, first, second, and third statistical moments (i.e., statistical parameters describing the shape of the distribution) are determined from the multiple sequencing depth signals, as described in more detail below.
[0059] In step 106 of FIG. 1 , tumor purity and tumor ploidy are determined for the sample based on the first, second, and third statistical moments of the multiple sequencing depth signals, for example, by solving a set of nonlinear equations generated using the method of moments, as described in more detail below.
[0060] In step 108 of FIG. 1, the copy number of the target genome segment is determined based on the sequencing depth signal of the target genome segment, tumor purity, and tumor ploidy.
[0061] In step 110 of FIG. 1, the determined copy number is optionally used as part of generating a genomic profile for the sample.
[0062] Process 100 may be implemented using, for example, one or more electronic devices implementing a software platform. In some examples, process 100 is implemented using a client-server system, with blocks of process 100 split in any manner between a server and a client device. In other examples, blocks of process 100 are split between a server and multiple client devices. Thus, while portions of process 100 are described herein as being implemented by a particular device of a client-server system, it should be understood that process 100 is not so limited. In other examples, process 100 is implemented using only client devices, or only multiple client devices. In process 100, some blocks are optionally combined, some blocks are optionally reordered, and some blocks are optionally omitted. In some examples, additional steps may be implemented in combination with process 100. Thus, the operations illustrated (and described in more detail below) are exemplary in nature and, therefore, should not be considered limiting.
[0063] Sequencing analysis of genome segments The method can include using one or more processors of a computer to obtain a plurality of sequencing depth signals for a plurality of genome segments in the genome of a sample, the sequencing depth signals being associated with the number of sequence reads aligned to the locus in the genome segments, and the plurality of genome segments includes a target genome segment. The sequencing depth signals can be normalized. For example, a process match control can be used to normalize the sequencing depth signals. Thereby, the normalized sequencing depth signals include information about localized copy number.
[0064] In some embodiments, the method further includes sequencing nucleic acid from the sample to generate sequence reads from the sample.
[0065] In some embodiments, sequence reads derived from a sample are generated by sequencing nucleic acids from the sample using a sequencing method, such as massively parallel sequencing.
[0066] Massively parallel sequencing technology, also referred to as next generation sequencing (NGS), can be used to identify copy number changes in samples. Examples of NGS technology include, but are not limited to, sequencing by synthesis, sequencing by ligation, and sequencing by hybridization. Examples of massively parallel sequencing processes include pyrosequencing used by 454 Corporation, Illumina's Solexa system, SOLiD™ (Sequencing by Oligonucleotide Ligation and Detection) system (Life Technologies Inc.), and Ion Torrent Sequencing systems such as Personal Genome Machine or Proton Sequencer (Life Technologies Inc). Various methods and techniques for NGS sample processing, read mapping, normalization, variant calling, and data interpretation are known in the art. For example, see Kulski, JK, 2016. Next-generation sequencing - an overview of the history, tools, and "omic" applications. Next generation sequencing - advances, applications and challenges, pp. 3-60. Quinn, TP, Erb, I., Richardson, MF and Crowley, TM, 2018. Understanding sequencing data as compositions: an outlook and review. Bioinformatics, 34(16), pp. 2870-2878.
[0067] In some embodiments, the method further comprises capturing a subset of the nucleic acid molecules from the plurality of nucleic acid molecules by using one or more hybridization bait molecules prior to sequencing, a process also known as target enrichment.
[0068] In some embodiments, the sequencing depth signal is normalized. Various methods and techniques of sequencing data normalization are known in the art and can be used in the methods described herein.
[0069] In some embodiments, the multiple sequencing depth signals of a sample (e.g., a tumor sample) are normalized using a control. In some embodiments, the control is a normal (i.e., tumor-free) sample. In some embodiments, the control is a process-matched normal sample.
[0070] In some embodiments, multiple sequencing depth signals are subjected to GC content bias correction using Lowess regression.
[0071] Various types of cancer or tumor samples can be used with the method. Examples of tumors include, but are not limited to, oligodendroglioma, ependymoma, meningioma, lymphoma, Ewing's sarcoma, chondrosarcoma, osteosarcoma, rhabdomyosarcoma, schwannoma, medulloblastoma, breast, adrenal, pancreatic, parathyroid, pituitary, thyroid, anal, colorectal, esophagus, gallbladder, stomach, liver cancer, small intestine, cervix, endometrium, uterus, fallopian tube, ovary, vagina, vulva, larynx, oropharynx, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, mesothelioma, non-small cell lung cancer, small cell lung cancer, AIDS-related lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma, myeloma, penis, prostate, melanoma, Kaposi's sarcoma, testicular, bladder, kidney, and urethral tumors.
[0072] The method can be used for individuals with any type of cancer.Non-limiting examples of cancer include melanoma (e.g., metastatic malignant melanoma), kidney cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), pancreatic cancer, breast cancer, colon cancer, lung cancer (e.g., non-small cell lung cancer), esophageal cancer, squamous cell carcinoma of the head and neck, liver cancer, ovarian cancer, cervical cancer, and thyroid cancer.
[0073] In some embodiments, the sample is from a patient with lung cancer, ovarian cancer, breast cancer, prostate cancer, or pancreatic cancer.
[0074] A sample containing tumor cells or tumor tissue (eg, a tumor sample) can be obtained, for example, from a biopsy taken from a patient.
[0075] The methods of the invention can be used on samples of various levels of tumor purity. In some embodiments, the tumor purity is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or 100%.
[0076] In some embodiments, tumor purity is within the range of about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, about 1% to about 6%, about 1% to about 7%, about 1% to about 8%, about 1% to about 9%, about 1% to about 10%, about 1% to about 15%, about 1% to about 20%, about 1% to about 25%, about 1% to about 30%, about 1% to about 35%, about 1% to about 40%, about 1% to about 45%, about 1% to about 50%, about 1% to about 55%, about 1% to about 60%, about 1% to about 65%, about 1% to about 70%, about 1% to about 75%, about 1% to about 80%, about 1% to about 85%, about 1% to about 90%, about 1% to about 95%, or about 1% to about 100%.
[0077] In some embodiments, tumor purity is in the range of about 2% to about 3%, about 2% to about 4%, about 2% to about 5%, about 2% to about 6%, about 2% to about 7%, about 2% to about 8%, about 2% to about 9%, about 2% to about 10%, about 2% to about 15%, about 2% to about 20%, about 2% to about 25%, about 2% to about 30%, about 2% to about 35%, about 2% to about 40%, about 2% to about 45%, about 2% to about 50%, about 2% to about 55%, about 2% to about 60%, about 2% to about 65%, about 2% to about 70%, about 2% to about 75%, about 2% to about 80%, about 2% to about 85%, about 2% to about 90%, about 2% to about 95%, or about 2% to about 100%.
[0078] In some embodiments, tumor purity is in the range of about 3% to about 4%, about 3% to about 5%, about 3% to about 6%, about 3% to about 7%, about 3% to about 8%, about 3% to about 9%, about 3% to about 10%, about 3% to about 15%, about 3% to about 20%, about 3% to about 25%, about 3% to about 30%, about 3% to about 35%, about 3% to about 40%, about 3% to about 45%, about 3% to about 50%, about 3% to about 55%, about 3% to about 60%, about 3% to about 65%, about 3% to about 70%, about 3% to about 75%, about 3% to about 80%, about 3% to about 85%, about 3% to about 90%, about 3% to about 95%, or about 3% to about 100%.
[0079] In some embodiments, tumor purity is within the range of about 4% to about 5%, about 4% to about 6%, about 4% to about 7%, about 4% to about 8%, about 4% to about 9%, about 4% to about 10%, about 4% to about 15%, about 4% to about 20%, about 4% to about 25%, about 4% to about 30%, about 4% to about 35%, about 4% to about 40%, about 4% to about 45%, about 4% to about 50%, about 4% to about 55%, about 4% to about 60%, about 4% to about 65%, about 4% to about 70%, about 4% to about 75%, about 4% to about 80%, about 4% to about 85%, about 4% to about 90%, about 4% to about 95%, or about 4% to about 100%.
[0080] In some embodiments, tumor purity is in the range of about 5% to about 6%, about 5% to about 7%, about 5% to about 8%, about 5% to about 9%, about 5% to about 10%, about 5% to about 15%, about 5% to about 20%, about 5% to about 25%, about 5% to about 30%, about 5% to about 35%, about 5% to about 40%, about 5% to about 45%, about 5% to about 50%, about 5% to about 55%, about 5% to about 60%, about 5% to about 65%, about 5% to about 70%, about 5% to about 75%, about 5% to about 80%, about 5% to about 85%, about 5% to about 90%, about 5% to about 95%, or about 5% to about 100%.
[0081] In some embodiments, tumor purity is within the range of about 10% to about 15%, about 10% to about 20%, about 10% to about 25%, about 10% to about 30%, about 10% to about 35%, about 10% to about 40%, about 10% to about 45%, about 10% to about 50%, about 10% to about 55%, about 10% to about 60%, about 10% to about 65%, about 10% to about 70%, about 10% to about 75%, about 10% to about 80%, about 10% to about 85%, about 10% to about 90%, about 10% to about 95%, or about 10% to about 100%.
[0082] In some embodiments, tumor purity is in the range of about 20% to about 25%, about 20% to about 30%, about 20% to about 35%, about 20% to about 40%, about 20% to about 45%, about 20% to about 50%, about 20% to about 55%, about 20% to about 60%, about 20% to about 65%, about 20% to about 70%, about 20% to about 75%, about 20% to about 80%, about 20% to about 85%, about 20% to about 90%, about 20% to about 95%, or about 20% to about 100%.
[0083] In some embodiments, tumor purity is in the range of about 30% to about 35%, about 30% to about 40%, about 30% to about 45%, about 30% to about 50%, about 30% to about 55%, about 30% to about 60%, about 30% to about 65%, about 30% to about 70%, about 30% to about 75%, about 30% to about 80%, about 30% to about 85%, about 30% to about 90%, about 30% to about 95%, or about 30% to about 100%.
[0084] In some embodiments, tumor purity is in the range of about 40% to about 45%, about 40% to about 50%, about 40% to about 55%, about 40% to about 60%, about 40% to about 65%, about 40% to about 70%, about 40% to about 75%, about 40% to about 80%, about 40% to about 85%, about 40% to about 90%, about 40% to about 95%, or about 40% to about 100%.
[0085] In some embodiments, tumor purity is in the range of about 50% to about 55%, about 50% to about 60%, about 50% to about 65%, about 50% to about 70%, about 50% to about 75%, about 50% to about 80%, about 50% to about 85%, about 50% to about 90%, about 50% to about 95%, or about 50% to 100%.
[0086] In some embodiments, the tumor purity is in the range of about 60% to about 65%, about 60% to about 70%, about 60% to about 75%, about 60% to about 80%, about 60% to about 85%, about 60% to about 90%, about 60% to about 95%, or about 60% to about 100%. In some embodiments, the tumor purity is in the range of about 70% to about 75%, about 70% to about 80%, about 70% to about 85%, about 70% to about 90%, about 70% to about 95%, or about 70% to about 100%. In some embodiments, the tumor purity is in the range of about 80% to about 85%, about 80% to about 90%, about 80% to about 95%, or about 80% to about 100%. In some embodiments, tumor purity ranges from about 90% to about 95%, from about 95% to about 100%, or from about 90% to 100%.
[0087] In some embodiments, the target genome segment comprises a gene of interest. The present disclosure can be used to determine the copy number of various genes of interest in a sample. Examples of genes related to tumorigenesis and / or cell transformation include MLL fusion genes, BCR-ABL, TEL-AML I, EWS-FL11, TLS-FUS, PAX3-FKHR, Bcl-2, AML1-ETO, AML1-MTG8, Ras, Fos PDGF, RET, APC, NF-1, Rb, p53, MDM2, etc.; overexpressed genes such as multidrug resistance genes; cyclins; β-catenin; telomerase genes; c-myc, n-myc, Bel-2, Erb-B1 and Erb-B2; and mutated genes such as Ras, Mos, Raf, and Met. Examples of tumor suppressor genes include, but are not limited to, p53, p21, RB1, WTI, NF1, VHL, APC, DAP kinase, p16, ARF, neurofibromin, and PTEN. Examples of genes that can be targeted by nucleic acid agents useful for anti-cancer therapy include genes encoding proteins associated with tumor migration, such as integrins, selectins, and metalloproteinases; vascular endothelial growth factor (VEGF) or VEGF-related proteins, such as those described in WO2011 / 097533 PCTfUS2011 / 023823 Included among these are anti-angiogenic genes that encode proteins that promote the formation of new blood vessels, such as VEGFr; anti-angiogenic genes that encode proteins that inhibit neovascularization, such as endostatin, angiostatin, and VEGF-R2; and genes that encode proteins such as interleukins, interferons, fibroblast growth factors (a-FGF and (3-FGF), insulin-like growth factors (e.g., IGF-1 and IGF-2), platelet-derived growth factor (PDGF), tumor necrosis factor (TNF), transforming growth factors (e.g., TGF-a and TGF-3, epidermal growth factor (EGF), keratinocyte growth factor (KGF), stem cell factor and its receptor c-Kit (SCF / c-Kit) ligand, CD40L / CD40, VLA-4 VCAM-1, ICAM-1 / LFA-1, hyalurin / CD44, and the like. As will be appreciated by those of skill in the art, the foregoing examples are not exhaustive.
[0088] In some embodiments, the gene of interest is the phosphatase and tensin homolog (PTEN) gene, the breast cancer 1 (BRCA1) gene, or the breast cancer 2 (BRCA2) gene.
[0089] In some embodiments, the method further comprises segmenting the genome to generate a plurality of genome segments. In some embodiments, the genome is segmented using a sequencing depth signal. In some embodiments, the genome is segmented using a circular binary segmentation (CBS) algorithm. In some embodiments, the genome is segmented using a method that also considers allele frequency.
[0090] The circular binary segmentation (CBS) algorithm divides the genome into equal copy number segments, and CBS recursively divides the sequencing depth signal data into individual segments until each segment is uniform, such that further division does not result in a statistically significant difference in signal level. Depending on the aneuploidy and data quality of a single sample, the number of segments can range from 22 to several hundred. Further details of CBS can be found in Olshenet al.Circular binary segmentation for the analysis of array-based DNA copy number data.Biostatistics,5(4):557-572,2004.
[0091] In some embodiments, S i If is a genome segment, then l i Let be the known length, and C i The tumor ploidy Ψ of a sample is
number
number
[0092] Similarly, the random variable f ij But segment S i represents the minor allele frequency (MAF) of the SNP in i But, S i is the copy number of the minor allele in i ≦C i and σ fi But segment S i If f is the SD of the SNP data in ij can be modeled as follows:
number
[0093] Statistical Moments The method may also include determining, using the one or more processors, a first statistical moment, a second statistical moment, and a third statistical moment from the plurality of sequencing depth signals for the plurality of genome segments.
[0094] The expressions for moments and central moments with respect to p(x) (probability mass function) and f(x) (probability density function) are as follows: ●The nth moment of X is expressed as E[Xn], where E[Xn] is:
number
number
[0095] Examples of moments and central moments may include: 1) The first moment, e.g., the average, e.g., the mean, which is a measure of central tendency of the data. 2) The second central moment, e.g., the variance, which measures the spread of the observations from the mean, e.g., the squared deviation of a random variable from its mean. 3) The third central moment, sometimes called skewness, when normalized or standardized, measures the symmetry of a probability distribution around the mean.
[0096] In some embodiments, the following moments can be used: R ij is a random variable representing the normalized sequencing depth signal (R o ij is R ij where i=1,…,I denotes the number of segments and j=1,…,n i is segment S i indicates the number of targets (e.g., loci) in segment S i Number of copies in C i Considering this, it can be assumed that: 1) R ij First moment:
number
number
number
[0097] In some embodiments, each segment R i The variable S represents the average sequencing depth signal within i can be established as follows:
number
[0098] Then, R including the first moment, the second central moment, and the third central moment i The moments of can be determined based on the data of all segments.
[0099] Method of moments for estimating tumor purity and ploidy The method can further include determining, using one or more processors, a tumor purity and a tumor ploidy for the sample from the first statistical moment, the second statistical moment, and the third statistical moment. In some embodiments, the method can determine the tumor purity and tumor ploidy using a method of moment estimation.
[0100] In short, the moment method uses the specimen moment (measured moment, M i ) to the parameter X i Theoretical moments (estimated moments, E(X i )) As shown below, by solving the resulting set of equations, the parameters of interest involved in the calculation of the theoretical moments can be estimated. An exemplary process for implementing the method of moments is as follows: 1) Equal the first sample moment M1 to the first theoretical moment E(X1). 2) Equating the second sample moment M2 with the second theoretical moment E(X2). 3) Sample moment M k , and the corresponding theoretical moment E(X k ), continuing to equal k=3, 4, ..., where k is equal to the number of parameters to be estimated. 4) Solve a set of equations for the parameters.
[0101] In some embodiments, a set of non-linear equations is established according to the method of moments. In some embodiments, determining tumor purity and tumor ploidy comprises solving the set of non-linear equations.
[0102] n i Assuming that, the number of targets in each segment can be made sufficiently large, and a set of nonlinear equations according to the method of moments is established in the following system of equations (4).
number
[0103] Specifically, the three unknown parameters: tumor purity p, tumor ploidy Ψ, and λ (i.e., the random variable in the distribution of copy numbers within each segment: Ci~Pois(λ)) can be solved by solving the above nonlinear equation system. The constraints on the three unknown parameters are 0 <p<1、Ψ> Note that 0 and λ>0.
[0104] In some embodiments, the parameters can be re-parameterized to facilitate the computation process. For example, the following parameterization can be implemented:
number
[0105] In some embodiments, solving the set of nonlinear equations includes using the R software package "BB."
[0106] Determining the copy number of a targeted genomic segment After determining the tumor purity and tumor ploidy, the copy number of the target genomic segment can then be determined using multiple sequencing depth signals for the target genomic segment.
[0107] For example, the estimated purity
number
number
number
number
number
[0108] Here, R o ij is the observed (normalized) sequencing depth signal for target j on segment i. Estimated C i If is negative, C i = 0. C i The solution is,
number
number
[0109] In some embodiments, the method further comprises determining a minor allele copy number for the target genome segment.
[0110] For example, each segment S i The minor allele M in i The copy number of
number
number
number
number
[0111] where f o ij is the observed minor allele frequency for target j on segment i. The estimated M i If is negative, M i = 0,
number
number
number
number
number
[0112] 2 provides a flow chart for an exemplary process 200 for determining copy number and minor allele copy number for a target genome segment. In step 202 of FIG. 2, a sequence depth signal R ij For example, sequence read data may be received from an input device, the sequence read data including a plurality of sequencing depth signals for a plurality of genome segments, the plurality of sequencing depth signals being associated with sequencing data derived from the sample, the plurality of genome segments including a target genome segment.
[0113] In step 204 of Figure 2, a segmentation method is applied to the normalized sequence depth signal data to segment the genome. In some examples, a segmentation method such as, for example, a circular binary segmentation (CBS) method can be applied to segment the genome into segments where each segment has the same copy number.
[0114] In step 206 of FIG. 2, an average sequencing depth signal is determined for each segment and used to estimate the first, second, and third moments for the distribution of normalized sequencing depth signals. For example, R o 1, …, R o I The value for each segment S i is determined from experimental data for E(R i ), V(R i ) and μ3(R i ) is used to estimate
[0115] In step 208 of FIG. 2, the tumor purity and tumor ploidy of the sample are determined by solving a set of nonlinear equations (eg, Equation (4)) generated by the method of moments.
[0116] In step 210 of FIG. 2, the number of copies, C i , and the copy number of the minor allele, M i , for each segment S i is estimated, for example, by solving equations (5) and (6).
[0117] When implemented by a computer, the method for determining the copy number of a target genomic segment in a genome of a sample comprises: a) receiving a dataset of sequencing information from an input device, receiving a dataset comprising a plurality of sequencing depth signals for a plurality of genomic segments, the plurality of sequencing depth signals being associated with sequencing data derived from the tumor sample, the plurality of genomic segments comprising a target genomic segment; b) automatically inputting the dataset into a model to predict the copy number of the target genomic segment, The model is configured to estimate a first statistical moment, a second statistical moment, and a third statistical moment from the plurality of normalized sequencing depth signals and predict a tumor purity value, a tumor ploidy value, and a copy number of the target genomic segment; c) outputting a predicted tumor purity value, a predicted tumor ploidy value, and a predicted copy number of the target genome segment; d) optionally displaying the output on a display device.
[0118] In some embodiments, the model can also predict and output a predicted minor allele copy number for the target genome segment, in addition to a predicted tumor purity value, a predicted tumor ploidy value, and a predicted copy number of the target genome segment.
[0119] Methods for determining copy number alterations (CNAs) In some examples, the method may further comprise determining copy number alterations (CNA) of the target genome segment in the sample based on the determined copy number of the target genome segment. Copy number alterations are distinct from single nucleotide base alterations (e.g., SNPs) and usually result from alterations of relatively large chromosomal fragments, for example ranging in size from several kilobases to whole chromosomes. CNAs are particularly found in cancers and may include deletions or amplifications of fragments of genomic material that play a major role in their development and progression.
[0120] 3 provides a flow chart of an exemplary process 300 for determining copy number changes of a target genome segment. In step 302 of FIG. 3, a plurality of sequencing depth signals are obtained for a plurality of genome segments in a sample, the plurality of genome segments including a target genome segment, and the plurality of sequencing depth signals are associated with sequencing data derived from the sample.
[0121] In step 304 of FIG. 3, first, second, and third statistical moments are determined from the plurality of sequencing depth signals.
[0122] In step 306 of FIG. 3, tumor purity and tumor ploidy are determined for the sample based on the first, second, and third statistical moments for the multiple sequencing depth signals, for example, by solving a set of nonlinear equations generated using the method of moments.
[0123] In step 308 of FIG. 3, the copy number of the target genome segment is determined based on the sequencing depth signal, tumor purity, and tumor ploidy for the target genome segment by solving additional nonlinear equations generated using, for example, the method of moments, as described elsewhere herein.
[0124] In step 310 of FIG. 3, the estimated copy number for the target genome segment in a sample is compared to the copy number for the target genome segment in a reference sample.
[0125] In step 312 of FIG. 3, copy number alterations (CANs) are identified for a target genomic segment in a sample by detecting a difference between the estimated copy number for the target genomic segment in the sample and the estimated copy number for a reference.
[0126] The reference copy number represents the copy number in a normal genome from which the copy number in a genome (e.g., sample genome or tumor genome) may deviate. The reference copy number may be derived from a control sample. In some embodiments, the control sample is, for example, a paired normal (i.e., non-tumor) sample. In some embodiments, the control sample is, for example, a process-matched normal control for the sample.
[0127] When implemented by a computer, determining copy number alterations (CNAs) of a target genomic segment in a sample includes: a) receiving a dataset of sequencing information from an input device, receiving a dataset comprising a plurality of sequencing depth signals for a plurality of genome segments and a reference copy number of a target genome segment, the plurality of sequencing depth signals being associated with sequencing data derived from the sample, the plurality of genome segments comprising the target genome segment; b) automatically inputting the dataset into a model to predict copy number alterations (CNAs) of the target genomic segment, inputting, the model being configured to estimate a first statistical moment, a second statistical moment, and a third statistical moment from the plurality of normalized sequencing depth signals, predict a tumor purity value, a tumor ploidy value, and a copy number of the target genome segment, and calculate a difference between the predicted copy number of the target genome segment and a reference copy number of the target genome segment; c) outputting the calculated difference between the predicted copy number of the target genome segment and the reference copy number of the target genome segment as a determined copy number alteration (CNA); d) optionally displaying the output on a display device.
[0128] In some embodiments, the method may further comprise using the determined copy number alterations (CNAs) as biomarkers in medical diagnosis and / or treatment. For further details on CNAs and their use as biomarkers, see, for example, Lu, Zhihao, et al. "Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer." Journal for immunotherapy of cancer 8.2 (2020), and Fumet, Jean-David, et al. "Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts." European Journal of Cancer 131 (2020): 40-50. For further details, also see the section below "Methods for selecting medical treatments."
[0129] Methods for determining loss of heterozygosity (LOH) The method may further include determining loss of heterozygosity (LOH) of a minor allele of the target genome segment based on the determined minor allele copy number of the target genome segment.
[0130] Loss of heterozygosity (LOH) refers to a change from heterozygosity to homozygosity at a polymorphic genomic locus of interest. A polymorphic locus (e.g., SNP) in the human genome can be heterozygous in an individual's germline because that individual typically receives one copy from the biological father and one copy from the biological mother. However, in somatic cells, this heterozygosity can change (through mutation) to homozygosity, i.e., LOH. LOH can result from multiple mechanisms. For example, in some cases, a locus on one chromosome can be deleted in somatic cells. Loci that remain present on other chromosomes (other non-sex chromosomes for males) are LOH loci because there is only one copy of that locus (instead of two copies) present in the genome of the affected cell. This type of LOH event results in a reduction in copy number. In other cases, a locus on one chromosome in a somatic cell (e.g., one non-sex chromosome for males) may be replaced with a copy of the locus from another chromosome, thereby eliminating any heterozygosity that may be present within the replaced locus. In such cases, the loci that remain present on each chromosome are LOH loci, and can be referred to as copy-neutral LOH loci.
[0131] 4 provides a flow chart of an exemplary process 400 for determining loss of heterozygosity (LOH) of a minor allele of a target genome segment. In step 402 of FIG. 4, a plurality of sequencing depth signals are obtained for a plurality of genome segments in a sample, the plurality of genome segments including a target genome segment, and the plurality of sequencing depth signals are associated with sequencing data derived from the sample.
[0132] In step 404 of FIG. 4, first, second, and third statistical moments are determined from the plurality of sequencing depth signals.
[0133] In step 406 of FIG. 4, tumor purity and tumor ploidy are determined for the sample based on the first, second, and third statistical moments for the multiple sequencing depth signals, for example, by solving a set of nonlinear equations generated using the method of moments.
[0134] In step 408 of FIG. 4, the copy number of the target genome segment is determined based on the sequencing depth signal, tumor purity, and tumor ploidy for the target genome segment by solving additional nonlinear equations generated using, for example, the method of moments, as described elsewhere herein.
[0135] In step 410 of FIG. 4, the minor allele copy number for the target genomic segment is determined.
[0136] In step 412 of FIG. 4, a determination is made whether the estimated copy number value for the target genomic segment is greater than 0 and less than (tumor ploidy+2).
[0137] In step 414 of FIG. 4, a determination is made whether loss of heterozygosity (LOH) has occurred for the minor allele of the target genomic segment, as described in more detail below.
[0138] In some embodiments, the steps for determining LOH of a minor allele of a target genome segment are as follows: i , the copy number of the minor allele M i and considering ploidy Ψ, Segment S i About: (1) C i ≧Ψ+2: Not LOH (amplified). (2) C i =0: Not LOH (loss). (3)0 <C i <Ψ+2: (a)C i =1 or C i = <Mi Or M i =0:LOH (b) Others: Not LOH.
[0139] Thus, LOH of a minor allele of a target genome segment can be identified by determining the presence of an estimated copy number of the target genome segment that is greater than 0 and less than the sum of the estimated ploidy and 2, and determining the presence of any one of the estimated copy number of the target genome segment equal to 1, the estimated copy number of the target genome segment equal to the estimated copy number of the minor allele of the target genome segment, and the estimated copy number of the minor allele of the target genome segment equal to 0.
[0140] In some embodiments, the LOH is the percent of genome-wide LOH (gLOH) of the sample. In some embodiments, the gLOH score as a percentage of the LOH segment length to the total genome length can be derived using the following formula:
number
[0141] For chromosomes where the ratio of LOH segment length to chromosome length exceeds 90%, the segment above is optionally excluded from the gLOH score calculation in the numerator of formula (7).
[0142] When implemented by a computer, determining loss of heterozygosity (LOH) of a minor allele of a target genomic segment comprises: a) receiving a dataset of sequencing information from an input device, Receiving a dataset comprising a predicted determined copy number of the target genome segment and a predicted minor allele copy number of the target genome segment; b) automatically inputting a dataset into a model to predict loss of heterozygosity (LOH), the model comprising: confirming a first occurrence of a predicted copy number of the target genomic segment that is greater than 0 and less than the sum of the predicted tumor ploidy and 2; 1) the predicted copy number of the targeted genomic segment, which is equal to 1; 2) the expected copy number of the target genomic segment equal to the expected minor allele copy number of the target genomic segment; or 3) confirming the presence of any one of the predicted minor allele copy number of the target genomic segment equal to 0; c) outputting a first value indicative of the presence of LOH if both the first and second presences are confirmed, or outputting a second value indicative of the absence of LOH if at least one of the first and second presences is not confirmed; d) optionally displaying the output on a display device.
[0143] Genome-wide LOH (gLOH) signatures can be used as biomarkers for homologous recombination deficiency (HRD). Homologous recombination deficiency (HRD) refers to a reduction or impairment of the homologous recombination process. Without wishing to be bound by theory, it is believed that homologous recombination deficient samples are unable or have a reduced ability to repair DNA damage, such as double-strand breaks, since homologous recombination is involved in DNA repair. Thus, samples that are HRD accumulate genomic errors or chromosomal abnormalities and can be used as biomarkers for HRD. LOH and its use in determining HRD are described in detail in published international application WO / 2011 / 160063, the entire contents of which are incorporated herein by reference. For further details, please also see the section below entitled "Methods for Selecting Medical Treatments."
[0144] Methods for determining tumor mutation burden (TMB) The method may further include determining a tumor mutational burden (TMB) of the sample based on the determined copy number, the determined tumor purity, and / or the determined tumor ploidy. Figure 5 shows a diagram of such an exemplary process.
[0145] Tumor mutational burden (TMB) is a measure of the abundance of somatic mutations in a tumor, calculated as the number of somatic mutations per megabase (i.e., million base pairs) of genomic sequence interrogated, i.e., mutations / Mb.
[0146] The method and technology for calculating TMB from next generation sequencing data is known in the art.However, various factors, including, for example, tumor purity, tumor ploidy, sequencing method and sequencing coverage, may hinder the successful estimation of TMB.A robust calculation method for estimating TMB needs to take these confounding factors into account.
[0147] The present disclosure provides highly stable and accurate estimates of tumor purity and tumor ploidy that can be used as inputs or cofactors in models to aid in the robust estimation of TMB.
[0148] Referring to FIG. 5, a flowchart of an exemplary process 3873 is provided, in which determining the tumor mutation burden (TMB) of a sample in the present method may include:
[0149] In step 502 of FIG. 5, multiple sequencing depth signals are obtained for multiple genome segments in a sample, the multiple genome segments including a target genome segment, and the multiple sequencing depth signals are associated with sequencing data derived from the sample.
[0150] In step 504 of FIG. 5, first, second, and third statistical moments are determined from the plurality of sequencing depth signals.
[0151] In step 506 of FIG. 5, tumor purity and tumor ploidy are determined for the sample based on the first, second, and third statistical moments for the multiple sequencing depth signals.
[0152] In step 508 of FIG. 5, the copy number of the target genome segment is determined based on the sequencing depth signal for the target genome segment, the tumor purity, and the tumor ploidy.
[0153] In step 520 of Figure 5, multiple genetic variants are identified using multiple sequencing depth signals for the sample.
[0154] In step 522 of FIG. 5, the plurality of genetic variants, along with the determined copy number, the determined tumor purity, and / or the determined tumor ploidy, are input into an algorithmic model configured to determine and output the origin of the plurality of genetic variants as somatic or germline.
[0155] In step 524 of FIG. 5, the tumor mutational burden (TMB) is determined for the sample by calculating the number of genetic variants of somatic origin per megabase of the sample genome.
[0156] When implemented by a computer, determining loss of heterozygosity (LOH) of a minor allele of a target genomic segment comprises: a) receiving a dataset of sequencing information from an input device, Receiving a dataset comprising a plurality of genetic variants from a plurality of sequencing depth signals of the sample, a predicted copy number, a predicted tumor purity, and / or a predicted tumor ploidy; b) automatically inputting the dataset into a model to predict tumor mutational burden (TMB), the model being configured to determine the origin of a plurality of genetic variants that are somatic or germline, and to calculate the number of genetic variants of somatic origin per megabase as the predicted TMB; c) outputting the TMB; and d) optionally displaying the output on a display device.
[0157] TMB can be used as a biomarker of response to immune checkpoint inhibitors. It is hypothesized that tumors with higher mutation burden are more likely to express neoantigens and induce stronger immune responses in the presence of immune checkpoint inhibitors. Thus, in some embodiments, the method further comprises using the identified tumor mutation burden (TMB) as a biomarker in medical diagnosis and / or treatment.
[0158] Further details regarding TMB and its use as a biomarker can be found, for example, in Chalmer et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9:34, Goodman et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 2017;16:2598-608, and Budczies et al. Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. Oncoimmunology 2018;7:e1526613. For further details, also see the section below entitled "Methods for selecting a medical treatment."
[0159] Methods for characterizing the mutational status of variants The method may further include characterizing the mutational status (e.g., somatic vs. germline, homozygous vs. heterozygous, and / or subclonal) of genetic variants in the sample based on the determined copy number, the determined tumor purity, and / or the determined tumor ploidy. Figure 6 shows a diagram of such an exemplary process.
[0160] Referring to FIG. 6, a flowchart of an exemplary process 600 is provided in which determining the tumor mutation burden (TMB) of a sample in the present method may include:
[0161] In step 602 of FIG. 6, multiple sequencing depth signals are obtained for multiple genome segments in a sample, the multiple genome segments including a target genome segment, and the multiple sequencing depth signals are associated with sequencing data derived from the sample.
[0162] In step 604 of FIG. 6, first, second, and third statistical moments are determined from the plurality of sequencing depth signals.
[0163] In step 606 of FIG. 6, tumor purity and tumor ploidy are determined for the sample based on the first, second, and third statistical moments for the multiple sequencing depth signals.
[0164] In step 608 of FIG. 6, the copy number of the target genome segment is determined based on the sequencing depth signal for the target genome segment, the tumor purity, and the tumor ploidy.
[0165] In step 620 of FIG. 6, genetic variants are identified based on multiple sequencing depth signals for the sample.
[0166] In step 622 of FIG. 6, an algorithm configured to determine the mutational status of a genetic variant is searched for.
[0167] In step 624 of FIG. 6, the mutational status of the genetic variant is characterized by inputting the genetic variant along with the determined copy number, the determined tumor purity, and / or the determined tumor ploidy into an algorithm and outputting the mutational status of the genetic variant.
[0168] When implemented by a computer, determining characterizing the mutation status of one or more genetic variants in the sample comprises: a) receiving a dataset of sequencing information from an input device, Receiving a dataset comprising one or more genetic variants from a plurality of sequencing depth signals of the sample; b) automatically inputting the dataset into a model to characterize the mutational status of the genetic variants, the model being configured to determine whether the genetic variants have a somatic or germline origin, homozygous or heterozygous zygosity, and / or subclonal or other clonal nature; c) outputting a mutation status determination for one or more genetic variants; and d) optionally displaying the output on a display device.
[0169] As an example, characterization of mutation status can be achieved by implementing the somatic-germline-zygosity (SGZ) algorithm (Sun, et al., “A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal”, PLoS computational biology, 14(2):e1005965, 2018).
[0170] In some embodiments, the mutational status of the genetic variants is somatic or germline origin, homozygous or heterozygous status, subclonal status, or a combination thereof. The present disclosure provides highly stable and accurate estimates of tumor purity, tumor ploidy, and CNA that can be used, for example, as inputs into a somatic-germline-zygosity (SGZ) algorithm to determine the somatic / germline status of one or more variants identified by sequencing a sample.
[0171] Somatic germline zygosity (SGZ) is a computational method for predicting the somatic vs. germline origin, homozygous vs. heterozygous status, or subclonal status (e.g., subclonal deletion events that cannot be matched by integer copy number values) of variants identified from high-throughput sequencing of samples. SGZ does not require patient-matched normal controls, allowing for broad application in clinical studies. SGZ predicts the somatic vs. germline status of each identified alteration by modeling the allele frequency (AF) of the alteration, taking into account tumor content, tumor ploidy, and local copy number. For further details, see also the section "Methods for selecting medical treatments" below.
[0172] How to Choose a Medical Procedure In some embodiments, the methods described herein provide biomarkers that can be used to indicate an individual's predisposition and susceptibility to disease, aid a clinician in diagnosing a medical condition, and / or predict an individual's response to a medical treatment and chance of survival. In some embodiments, the biomarkers disclosed herein can be used for etiology, prognosis, diagnosis, and targeting therapy in personalized medicine.
[0173] Biomarkers are useful in many aspects of medical research and clinical practice including, for example, diagnosing disease or predicting the risk of disease, monitoring healthy people to detect early signs of disease, determining whether a treatment is effective, targeting specific groups of people who may benefit from particular drugs, and producing safer drugs by predicting potential adverse effects earlier.
[0174] Biomarkers can be any biological indicator that can be measured. For example, biomarkers can be measurements from cellular and molecular entities such as DNA, RNA, proteins, metabolites, or they can be measurements from genetic and physiological characteristics such as traits. Biomarkers can be either quantitative or qualitative. Qualitative biomarkers can be involved in pathogenic process detection within a yes / no or presence / absence analysis, while quantitative biomarkers are involved in pathogenic process detection with threshold or dose effects.
[0175] In some embodiments, the biomarkers disclosed herein are selected from the group consisting of copy number of a genome segment, copy number of a minor allele of a genome segment, tumor purity, tumor ploidy, copy number alteration (CNA), loss of heterozygosity (LOH), genome-wide loss of heterozygosity (gLOH), tumor mutational burden (TMB), and mutational status of a variant.
[0176] In some embodiments, the present disclosure provides methods for selecting a treatment based on the biomarkers described herein.
[0177] Based on CNA Thus, the method includes selecting a treatment for an individual with cancer, comprising: a) determining copy number alterations (CNAs) in a sample from an individual, the CNAs being determined according to a method of any one of the preceding embodiments; b) using the determined CNAs as biomarkers to predict an individual's response to one or more treatment options; and and c) selecting a suitable treatment for the individual from one or more treatment options based on the predicted response.
[0178] In some embodiments, the methods may further include administering a selected treatment to the individual.
[0179] In some embodiments, the selected treatment is administration of a checkpoint inhibitor, hi some embodiments, the checkpoint inhibitor is selected from the group consisting of a PD-1 inhibitor, a PD-Ll inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, an IDO(1 / 2) inhibitor, a TIGIT inhibitor, and a B7-H3 inhibitor.
[0180] FIG. 7 provides a flow chart of an exemplary process 700 for selecting a treatment for an individual with cancer by using determined copy number alterations (CNAs) as biomarkers.
[0181] In step 702 of FIG. 7, copy number alterations (CNAs) are identified in a sample from an individual according to any of the methods disclosed herein.
[0182] In step 704 of FIG. 7, an individual's response to one or more treatment options is predicted based on the identified CNAs, where the CNAs serve as biomarkers, for example, for a disease state.
[0183] In step 706 of FIG. 7, a treatment option is selected from one or more treatment options appropriate for the individual based on the predicted response.
[0184] When implemented by a computer, selecting a treatment for an individual with cancer based on copy number alterations (CNAs) comprises: a) receiving a dataset of sequencing information from an input device, Receiving a dataset comprising one or more copy number alterations (CNAs) in one or more genomic segments in a sample from an individual; b) automatically inputting the dataset into a model to predict an individual's response to one or more treatment options, the response being associated with one or more CNAs; and c) outputting the predicted response; and d) optionally displaying the output on a display device; and e) triggering a selection of a treatment from one or more treatment options based on the predicted response.
[0185] In some embodiments, the CNA is associated with a gene of interest, such as the phosphatase and tensin homolog (PTEN) gene, the breast cancer 1 (BRCA1) gene, or the breast cancer 2 (BRCA2) gene.
[0186] Based on LOH In another aspect, the method comprises selecting a treatment for an individual having cancer, comprising: a) determining loss of heterozygosity (LOH) in a sample from an individual, wherein LOH is determined according to a method of any one of the preceding embodiments; b) using the determined LOH as a biomarker to predict an individual's response to one or more treatment options; and and c) selecting a suitable treatment for the individual from one or more treatment options based on the predicted response.
[0187] FIG. 8 provides a flow chart for an exemplary process for selecting a treatment for an individual with cancer by using determined loss of heterozygosity (LOH) as a biomarker.
[0188] In step 802 of FIG. 8, loss of heterozygosity (LOH) is identified in a sample from an individual according to any of the methods disclosed herein.
[0189] In step 804 of FIG. 8, an individual's response to one or more treatment options is predicted based on the identified LOH, where the LOH serves as a biomarker, for example, for a disease state.
[0190] In step 806 of FIG. 8, a treatment option is selected from one or more treatment options appropriate for the individual based on the predicted response.
[0191] In some embodiments, the LOH is the LOH of the minor allele of the target genome segment. In some embodiments, the method further comprises calculating genome-wide loss of heterozygosity (gLOH) as a percentage of the LOH segment length in the entire genome length.
[0192] In some embodiments, predicting the individual's response to one or more treatment options comprises detecting a difference between the gLOH value and a predetermined threshold value.
[0193] In some embodiments, the methods may further include administering a selected treatment to the individual.
[0194] In some embodiments, the selected treatment is administration of a checkpoint inhibitor, hi some embodiments, the checkpoint inhibitor is selected from the group consisting of a PD-1 inhibitor, a PD-Ll inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, an IDO(1 / 2) inhibitor, a TIGIT inhibitor, and a B7-H3 inhibitor.
[0195] When implemented by a computer, selecting a treatment for an individual with cancer based on percent genome-wide LOH (gLOH) comprises: a) receiving a dataset of sequencing information from an input device, Receiving a dataset comprising a rate of genome-wide LOH (gLOH) in a sample from an individual and one or more pre-defined thresholds associated with one or more treatment options; b) automatically inputting the dataset into a model for predicting an individual's response to one or more treatment options, the model being configured to compare the gLOH to a predefined threshold for each of the one or more treatment options and output the one or more comparisons as a predicted response; c) outputting the predicted response; and d) optionally displaying the output on a display device; and e) triggering a selection of a treatment from one or more treatment options based on the predicted response.
[0196] In some embodiments, the model is configured to determine whether gLOH is greater than a predetermined threshold for each of one or more treatment options and output the one or more determinations as a predicted response.
[0197] Based on TMB In yet another aspect, the method comprises selecting a treatment for an individual having cancer, comprising: a) determining a tumor mutational burden (TMB) in a sample from an individual, wherein the TMB is determined according to the method of any one of the preceding embodiments; b) using the determined TMB as a biomarker to predict an individual's response to one or more treatment options; and c) selecting a suitable treatment for the individual from one or more treatment options based on the predicted response.
[0198] FIG. 9 provides a flow chart of an exemplary process 900 for selecting a treatment for an individual with cancer by using a determined tumor mutation burden (TMB) as a biomarker.
[0199] In step 902 of FIG. 9, tumor mutational burden (TMB) is identified in a sample from an individual according to any of the methods disclosed herein.
[0200] In step 904 of FIG. 9, an individual's response to one or more treatment options is predicted based on the identified TMB, where TMB serves as a biomarker, for example, for a disease state.
[0201] In step 906 of FIG. 9, a treatment option is selected from one or more treatment options appropriate for the individual based on the predicted response.
[0202] In some embodiments, predicting an individual's response to one or more treatment options comprises detecting a difference between the TMB value and a predetermined threshold value.
[0203] In some embodiments, the method may further include administering a selected treatment to the individual. In some embodiments, the selected treatment is administration of a checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of a PD-1 inhibitor, a PD-Ll inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, an IDO(1 / 2) inhibitor, a TIGIT inhibitor, and a B7-H3 inhibitor.
[0204] Based on mutation status In yet another aspect, the method comprises selecting a treatment for an individual having cancer, comprising: a) characterizing a mutation status of a genetic variant in a sample from an individual, wherein the mutation status is characterized according to the method of any one of the preceding embodiments; b) predicting an individual's response to one or more treatment options based on the characterized mutation status of the genetic variant; and and c) selecting a suitable treatment for the individual from one or more treatment options based on the predicted response.
[0205] 10 provides a flowchart of an exemplary process 1000 for selecting a treatment for an individual with cancer based on the characterized mutational status of a genetic variant. In some embodiments, the mutational status of the genetic variant is somatic or germline origin, homozygous or heterozygous status, subclonal status, or a combination thereof.
[0206] In step 1020 of FIG. 10, the mutation status of the genetic variant is identified in a sample from the individual according to any of the methods disclosed herein.
[0207] In step 1040 of FIG. 10, an individual's response to one or more treatment options is predicted based on the characterized mutation status of a genetic variant, where the mutation status of the genetic variant serves as a biomarker, for example, for a disease state.
[0208] In step 1060 of FIG. 10, a treatment option is selected from one or more treatment options appropriate for the individual based on the predicted response.
[0209] In some embodiments, the mutational status of a genetic variant is the origin of the genetic variant, which is somatic or germline.
[0210] When implemented by a computer, selecting a treatment for an individual having cancer based on variant mutation status comprises: a) receiving a dataset of sequencing information from an input device, receiving a dataset including one or more mutation states associated with one or more genetic variants from a sample from an individual; b) automatically inputting the dataset into a model configured to predict an individual's response to one or more treatment options based on one or more mutational status; c) outputting the predicted response; and d) optionally displaying the output on a display device; and e) triggering a selection of a treatment from one or more treatment options based on the predicted response.
[0211] The methods for selecting treatments by using the biomarkers disclosed herein may benefit individuals with any type of cancer. Non-limiting examples of cancers include, but are not limited to, B-cell cancer (e.g., multiple myeloma), melanoma, breast cancer, lung cancer (such as non-small cell lung cancer or NSCLC), bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine or appendicular cancer, and the like. Cancer of the thyroid gland, salivary gland cancer, thyroid cancer, adrenal adenocarcinoma, osteosarcoma, chondrosarcoma, cancer of the blood tissue, adenocarcinoma, inflammatory myofibroblastic tumor, gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma NHL, soft tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelial sarcoma, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medullary These include blastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, essential thrombocythemia, agnogenic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familial hypereosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, and carcinoma-like tumors.
[0212] In some embodiments, the cancer is lung cancer, ovarian cancer, breast cancer, prostate cancer, or pancreatic cancer.
[0213] Various types of treatments can be used with the methods disclosed herein. Examples of cancer treatments include, but are not limited to, active surveillance, observation, surgical intervention, chemotherapy, immunotherapy, radiation therapy (such as external beam radiation therapy, stereotactic radiosurgery (gamma knife), and fractionated stereotactic radiation therapy (FSR)), local therapy, systemic therapy, vaccine therapy, viral therapy, molecular target therapy, or combinations thereof.
[0214] In some embodiments, the selected treatment is drug administration, chemotherapy, radiation therapy, immunotherapy, and / or gene therapy.
[0215] Various types of drugs may be used with the methods disclosed herein. Non-limiting examples of anti-cancer drugs include sorafenib, regorafenib, imatinib, eribulin, gemcitabine, capecitabine, pazopanib, lapatinib, dabrafenib, sutinib malate, crizotinib, everolimus, trisirolimus, sirolimus, axitinib, gefitinib, anastrol, bicalutamide, fulvestrant, ralitrex, pemetrexed, goserin acetate, erlotinib, vemurafenib, bizididibe, tamoxifen citrate, paclitaxel, doxorubicin, dazolinib ... These include cetaxel, cabazitaxel, oxaliplatin, dibuaflibercept, bevacizumab, trastuzumab, pertuzumab, pantiumumab, taxanes, bleomycin, melphalen, plumbagin, camptosar, mitomycin-C, doxorubicin, pegylated doxorubicin, forfoli 5-fluorouracil, temozolomide, pasireotide, tegafur, gimeracil, oterasin, itraconazole, bortezomib, lenalidomide, and romidepsin.
[0216] Examples of cancer chemotherapeutic agents include, but are not limited to, doxorubicin, epirubicin, 5-fluorouracil, paclitaxel, docetaxel, cisplatin, bleomycin, melphalen, plumbagin, irinotecan, mitomycin C, and mitoxantrone. By way of example, some other cancer chemotherapy drugs that may be used and may be in clinical trials include resminostat, tasquinimod, refametinib, lapatinib, tyverb, arendil, pasireotide, signifol, ticilimumab, tremelimumab, lansoprazole, PrevOnco, ABT-869, linifanib, tivantinib, tarceva, erlotinib, stivarga, regorafenib, fluorosorafenib, brivanib, liposomal doxorubicin, lenvatinib, ramucirumab, peretinoin, rutico, muparfostat, tesno, tegafur, gimeracil, oteracil, and orantinib.
[0217] Examples of cellular targets on which cancer drugs may have an effect include immune checkpoint proteins, mTORC, RAF kinase, MEK kinase, phosphoinositol kinase 3, fibroblast growth factor receptor, multiple tyrosine kinases, human epidermal growth factor receptor, vascular endothelial growth factor, other angiogenic factors, heat shock proteins; Smo (smooth) receptor, FMS-like tyrosine kinase 3 receptor, apoptosis protein inhibitors, cyclin-dependent kinases, deacetylases, ALK tyrosine kinase receptor, serine / threonine-protein kinase Pim-1, porcupine acyltransferase, hedgehog pathway, protein kinase C, mDM2, Glypciin 3, ChK1, hepatocyte growth factor MET receptor, epidermal growth factor domain-like 7, Notch pathway, Src family kinases, DNA methyltransferases, DNA intercalators, thymidine synthase, microtubule function disrupting agents, DNA crosslinking agents, DNA strand breakers, DNA alkylating agents, JNK-dependent p53 Ser15 phosphorylation inducers, DNA topoisomerase inhibitors, Bcl-2, and free radical generators.
[0218] In some embodiments, the treatment is a monotherapy. In some embodiments, the treatment is administering an immune checkpoint inhibitor to the individual.
[0219] In some embodiments, the treatment is a combination treatment. In some embodiments, the treatment is any combination selected from the group consisting of chemotherapy, administering engineered chimeric antigen receptor (CAR) T cells, administering an immune checkpoint inhibitor, and radiation therapy. In some embodiments, the chemotherapy is administering a drug selected from the group consisting of histone deacetylase inhibitors (HDACs), temozolomide, dacarbazine (DTIC), vemurafenib, dabrafenib, and trametinib. In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG3 inhibitors, IDO(1 / 2) inhibitors, TIGIT inhibitors, and B7-H3 inhibitors.
[0220] In some embodiments, selecting a treatment includes selecting a drug administration regimen, including the amount of drug to be given at a particular time and a schedule for administering the drug.
[0221] Additionally, the method of selecting a treatment may include generating or updating a report from the selection of the treatment. In some embodiments, the method further includes transmitting the report to the individual or to a clinician. In some embodiments, the method further includes storing the report on a non-transitory computer readable storage medium. In some embodiments, the method further includes displaying the report on a computer display.
[0222] How to use In some examples, the disclosed methods include (i) obtaining a sample from a subject (e.g., a subject suspected of having or determined to have cancer); (ii) extracting nucleic acid molecules (e.g., a mixture of tumor and non-tumor nucleic acid molecules) from the sample; (iii) ligating one or more adapters (e.g., one or more amplification primers, flow cell adapter sequences, substrate adapter sequences, or sample index sequences) to the nucleic acid molecules extracted from the sample; (iv) amplifying the nucleic acid molecules (e.g., using a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique); and (v) hybridizing the nucleic acid molecules to one or more bait molecules, each of which comprises one or more nucleic acid molecules that each comprise a region complementary to a region of the captured nucleic acid molecule (e.g., a region complementary to a region of the captured nucleic acid molecule). (vi) capturing the nucleic acid molecules from the amplified nucleic acid molecules (by hybridization); (vi) sequencing the nucleic acid molecules extracted from the sample (or library proxies derived therefrom), e.g., using a next-generation (e.g., massively parallel) sequencer, e.g., using next-generation (e.g., massively parallel) sequencing technology, whole genome sequencing (WGS) technology, whole exome sequencing technology, targeted sequencing technology, direct sequencing technology, or Sanger sequencing technology; and (vii) generating, displaying, transmitting, and / or delivering a report (e.g., electronic report, web-based report, or paper report) to a subject (or patient), a caregiver, a health care provider, a physician, an oncologist, an electronic medical record system, a hospital, a clinic, a medical clinic, a third party payer, an insurance company, or a government agency. In some examples, the report comprises an output from a method described herein. In some examples, all or a portion of the report can be displayed in a graphical user interface of an online or web-based health care portal. In some examples, the report is transmitted over a computer network or a peer-to-peer connection.
[0223] The disclosed methods can be used with any of a variety of samples. For example, in some examples, the sample can include a tissue biopsy sample, a liquid biopsy sample, or a normal control. In some examples, the sample can be a liquid biopsy sample and can include blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva. In some examples, the sample can be a liquid biopsy sample and can include circulating tumor cells (CTCs). In some examples, the sample can be a liquid biopsy sample and can include cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof.
[0224] In some examples, the nucleic acid molecules extracted from the sample can include a mixture of tumor nucleic acid molecules and non-tumor nucleic acid molecules. In some examples, the tumor nucleic acid molecules can be derived from the tumor part of the heterogeneous tissue biopsy sample, and the non-tumor nucleic acid molecules can be derived from the normal part of the heterogeneous tissue biopsy sample. In some examples, the sample can include a liquid biopsy sample, the tumor nucleic acid molecules can be derived from the circulating tumor DNA (ctDNA) fraction of the liquid biopsy sample, and the non-tumor nucleic acid molecules can be derived from the non-tumor cell-free DNA (cfDNA) fraction of the liquid biopsy sample.
[0225] In some examples, the disclosed methods for determining copy number or copy number alterations may be used to diagnose (or as part of the diagnosis of) the presence of a disease or other condition in a subject (e.g., patient) (e.g., cancer, genetic disorders (such as Down's syndrome and fragile X), neurological disorders, or any other disease type where detection of a variant, e.g., copy number alteration, is relevant to diagnosing, treating, or predicting the disease). In some examples, the disclosed methods may be applicable to the diagnosis of any of a variety of cancers, as described elsewhere herein.
[0226] In some examples, the disclosed methods for determining copy number or copy number changes can be used to predict genetic disorders in fetal DNA (e.g., for invasive or non-invasive prenatal testing). For example, sequence read data obtained by sequencing fetal DNA extracted from samples obtained using invasive amniocentesis, chorionic villus sampling (cVS), or fetal umbilical cord sampling techniques, or samples obtained using non-invasive sampling of cell-free DNA (cfDNA) samples (including a mixture of maternal and fetal cfDNA) can be processed according to the disclosed methods to identify variants, e.g., copy number changes, associated with, for example, Down's syndrome (trisomy 21), trisomy 18, trisomy 13, extra copies or missing copies of X and Y chromosomes.
[0227] In some examples, the disclosed methods for determining copy number or copy number alterations can be used to select subjects (e.g., patients) for clinical trials, e.g., based on the copy number values determined for one or more loci. In some examples, patient selection for clinical trials, e.g., based on the identification of copy number alterations at one or more loci, can accelerate the development of targeted therapies and improve the medical outcomes of treatment decisions.
[0228] In some examples, the disclosed methods for determining copy number or copy number alterations can be used to select an appropriate therapy or treatment (e.g., an anti-cancer therapy or treatment) for a subject. In some examples, for example, the anti-cancer therapy or treatment can include the use of poly(ADP-ribose) polymerase inhibitors (PARPi), platinum compounds, chemotherapy, radiation therapy, targeted therapy (e.g., immunotherapy), surgery, or any combination thereof.
[0229] In some examples, the disclosed methods for determining copy number alterations can be used in treating a disease (e.g., cancer) in a subject. For example, in response to determining copy number alterations for one or more genetic loci using any of the methods disclosed herein, an effective amount of an anti-cancer therapy or treatment can be administered to the subject.
[0230] In some examples, the disclosed methods for determining copy number or copy number changes can be used to monitor disease progression or recurrence in a subject (e.g., cancer or tumor progression or recurrence). For example, in some examples, the methods may be used to determine (e.g., detect) copy number changes in a first sample obtained from a subject at a first time point, and to determine (e.g., detect) copy number changes in a second sample obtained from the subject at a second time point, and comparison of the first and second determinations allows for monitoring disease progression or recurrence. In some examples, the first time point is selected before the patient is administered a therapy or treatment, and the second time point is selected after the subject is administered a therapy or treatment.
[0231] In some examples, the disclosed methods can be used to adjust a therapy or treatment (e.g., an anti-cancer treatment or anti-cancer therapy) for a subject, for example, by adjusting the treatment dose and / or selecting a different treatment in response to a change in the detected copy number alteration.
[0232] In some instances, copy number or copy number change values determined using the disclosed methods can be used as prognostic or diagnostic indicators associated with a sample. For example, in some instances, a prognostic or diagnostic indicator can include an indication of the presence of a disease (e.g., cancer) in a sample, an indication of the likelihood that a disease (e.g., cancer) is present in a sample, an indication of the likelihood (i.e., risk factor) that a subject from whom the sample was derived will develop a disease (e.g., cancer), or an indication of the likelihood that a subject from whom the sample was derived will respond to a particular therapy or treatment.
[0233] In some examples, the disclosed methods for determining copy number or copy number alterations can be performed as part of a genomic profiling process that includes identifying the presence of variant sequences at one or more loci in a sample from a subject as part of detecting, monitoring, predicting risk factors, or selecting a treatment for a particular disease (e.g., cancer). In some examples, the variant panel selected for genomic profiling can include detection of variant sequences at a selected set of loci. In some examples, the variant panel selected for genomic profiling can include detection of variant sequences at multiple loci via comprehensive genomic profiling (CGP), a next-generation sequencing (NGS) approach used to evaluate hundreds of genes (including associated cancer biomarkers) in a single assay. Including the disclosed methods for determining copy number or detecting copy number alterations as part of the genomic profiling process (or including output from the disclosed methods for determining copy number or detecting copy number alterations as part of a subject's genomic profile) can improve the validity of, e.g., disease detection calls and treatment decisions made based on the genomic profile, e.g., by independently confirming the presence of copy number alterations in a given patient sample.
[0234] In some examples, a genomic profile may include information about the presence of genes (or variant sequences thereof), copy number variations, epigenetic traits, proteins (or modifications thereof), and / or other biomarkers in an individual's genome and / or proteome, as well as the individual's corresponding phenotypic traits, and information about the interactions between genetic or genomic traits, phenotypic traits, and environmental factors.
[0235] In some examples, the subject's genomic profile can include results from a comprehensive genomic profiling (CGP) test, a nucleic acid sequencing-based test, a gene expression profiling test, a cancer hotspot panel test, a DNA methylation test, a DNA fragmentation test, an RNA fragmentation test, or any combination thereof.
[0236] In some examples, the method may further include administering or applying a treatment or therapy (e.g., an anti-cancer agent, anti-cancer treatment, or anti-cancer therapy) to the subject based on the generated genomic profile. An anti-cancer agent or anti-cancer treatment may refer to a compound that is effective in treating cancer cells. Examples of anti-cancer agents or anti-cancer treatments include, but are not limited to, alkylating agents, antimetabolites, natural products, hormones, chemotherapy, radiation therapy, immunotherapy, surgery, or treatments configured to target defects in a particular cell signaling pathway, such as defects in the DNA mismatch repair (MMR) pathway.
[0237] sample The disclosed methods and systems may be used with any of a variety of samples (also referred to herein as specimens) containing nucleic acids (e.g., DNA or RNA) collected from a subject (e.g., a patient). Examples include, but are not limited to, a tumor sample, a tissue sample, a biopsy sample, a blood sample (e.g., a peripheral whole blood sample), a plasma sample, a serum sample, a lymph sample, a saliva sample, a sputum sample, a urine sample, a gynecological fluid sample, a circulating tumor cell (CTC) sample, a cerebrospinal fluid (CSF) sample, a pericardial fluid sample, a pleural fluid sample, an ascites (peritoneal fluid) sample, a feces (or stool) sample, or other bodily fluid, secretion, and / or excretion sample (or a cell sample derived therefrom). In certain examples, the sample may be a frozen sample or a formalin-fixed paraffin-embedded (FFPE) sample.
[0238] In some examples, samples may be collected by tissue resection (e.g., surgical resection), needle biopsy, bone marrow biopsy, bone marrow aspirate, skin biopsy, endoscopic biopsy, fine needle aspiration, oral swab, nasal swab, vaginal swab, or cytological smear, scraping, lavage or washing (such as luminal lavage or bronchoalveolar lavage), or the like.
[0239] In some examples, the sample is a liquid biopsy sample and may include, for example, whole blood, plasma, serum, urine, stool, sputum, saliva, or cerebrospinal fluid. In some examples, the sample is a liquid biopsy sample and may include circulating tumor cells (CTCs). In some examples, the sample is a liquid biopsy sample and may include cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof.
[0240] In some examples, the sample may include one or more pre-malignant or malignant cells. As used herein, a pre-malignant tumor refers to a cell or tissue that is not yet malignant, but is preparing to become malignant. In certain examples, the sample may be obtained from a solid tumor, a soft tissue tumor, or a metastatic lesion. In certain examples, the sample may be obtained from a hematological malignancy or a pre-malignancy. In other examples, the sample may include tissue or cells from a surgical margin. In certain examples, the sample may include tumor-infiltrating lymphocytes. In some examples, the sample may include one or more non-malignant cells. In some examples, the sample may be or be part of a primary tumor or metastasis (e.g., a metastasis biopsy sample). In some examples, the sample may be obtained from a site (e.g., a tumor site) with the highest percentage of tumor (e.g., tumor cells) compared to an adjacent site (e.g., a site adjacent to the tumor). In some examples, a sample may be obtained from a site (e.g., a tumor site) with the largest tumor lesion (e.g., the largest number of tumor cells as viewed under a microscope) compared to an adjacent site (e.g., a site adjacent to the tumor).
[0241] In some examples, the disclosed methods may further include analyzing a primary control (e.g., a normal tissue sample). In some examples, the disclosed methods may further include determining whether a primary control is available and, if so, isolating a control nucleic acid (e.g., DNA) from the primary control. In some examples, the sample may include an optional normal control (e.g., normal adjacent tissue (NAT)) if a primary control is not available. In some examples, the sample may be or include histologically normal tissue. In some examples, the method includes evaluating a sample, e.g., a histologically normal sample (e.g., from a surgical tissue margin), using a method described herein. In some examples, the disclosed methods may further include obtaining a subsample enriched in non-tumor cells, e.g., by macro-dissecting non-tumor tissue from the NAT in a sample without a primary control. In some examples, the disclosed methods may further include determining that a primary control and NAT are unavailable and marking the sample for analysis without a matching control.
[0242] In some examples, samples obtained from histologically normal tissue (e.g., from otherwise histologically normal tissue margins) may still contain genetic alterations, such as variant sequences described herein. Thus, the method may further include reclassifying the sample based on the presence of the detected genetic alteration. In some examples, multiple samples (e.g., from different subjects) are processed simultaneously.
[0243] The disclosed methods and systems may be applied to the analysis of nucleic acids extracted from various tissue samples (or disease states thereof), such as any of solid tissue samples, soft tissue samples, metastatic lesions, or liquid biopsy samples. Examples of tissues include, but are not limited to, connective tissue, muscle tissue, nervous system tissue, epithelial tissue, and blood. Tissue samples may be collected from any organ within an animal or human body. Examples of human organs include, but are not limited to, the brain, heart, lung, liver, kidney, pancreas, spleen, thyroid, breast, uterus, prostate, large intestine, small intestine, bladder, bone, skin, etc.
[0244] In some examples, the nucleic acid extracted from the sample may include deoxyribonucleic acid (DNA) molecules. Examples of DNA that may be suitable for analysis by the disclosed methods include, but are not limited to, genomic DNA or fragments thereof, mitochondrial DNA or fragments thereof, cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA). Cell-free DNA (cfDNA) is composed of fragments of DNA released from normal and / or cancer cells during apoptosis and necrosis, circulating in the bloodstream and / or accumulating in other body fluids. Circulating tumor DNA (ctDNA) is composed of fragments of DNA released from cancer cells and tumors, circulating in the bloodstream and / or accumulating in other body fluids.
[0245] In some instances, DNA is extracted from nucleated cells from a sample. In some instances, a sample has low nucleated cellularity, for example, when the sample is composed primarily of red blood cells, diseased cells containing excess cytoplasm, or tissue with fibrosis. In some instances, a sample with low nucleated cellularity may require more, for example, a larger tissue volume, for DNA extraction.
[0246] In some examples, the nucleic acid extracted from the sample may include ribonucleic acid (RNA) molecules. Examples of RNA that may be suitable for analysis by the disclosed methods include, but are not limited to, total cellular RNA, total cellular RNA after depletion of specific abundance RNA sequences (e.g., ribosomal RNA), cell-free RNA (cfRNA), messenger RNA (mRNA) or fragments thereof, poly(A)-tailed mRNA fraction of total RNA, ribosomal RNA (rRNA) or fragments thereof, transfer RNA (tRNA) or fragments thereof, and mitochondrial RNA or fragments thereof. In some examples, RNA may be extracted from the sample and converted to complementary DNA, for example, using a reverse transcription reaction. In some examples, cDNA is produced by random primed cDNA synthesis. In other examples, cDNA synthesis is initiated at the poly(A) tail of mature mRNA by priming with an oligo(dT)-containing oligonucleotide. Methods for depletion, poly(A) enrichment, and cDNA synthesis are well known to those skilled in the art.
[0247] In some examples, the sample may contain tumor content, including, for example, tumor cells or tumor cell nuclei. In some examples, the sample may contain tumor content with at least 5-50%, 10-40%, 15-25%, or 20-30% tumor cell nuclei. In some examples, the sample may contain tumor content of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% tumor cell nuclei. In some examples, the percentage of tumor nuclei is determined (e.g., calculated) by dividing the number of tumor cells in the sample by the total number of all cells in the sample that have nuclei. In some examples, for example, when the sample is a liver sample containing hepatocytes, a different tumor content calculation may be required due to the presence of hepatocytes with double or more than double nuclei, the presence of other DNA content, e.g., non-hepatocyte, somatic cell nuclei. In some examples, the sensitivity of detection of genetic alterations, e.g., variant sequences, or the sensitivity of determination of, e.g., microsatellite instability, may depend on the tumor content of the sample. For example, a sample with a lower tumor content may result in a lower sensitivity of detection for a sample of a given size.
[0248] In some instances, as described above, the sample contains nucleic acid (e.g., DNA, RNA (or cDNA derived from RNA), or both), e.g., from a tumor or from normal tissue. In certain instances, the sample may further contain non-nucleic acid components, e.g., cells, proteins, carbohydrates, or lipids, e.g., from the tumor or normal tissue.
[0249] subject In some examples, the sample is obtained (e.g., collected) from a subject (e.g., a patient) having or suspected of having a condition or disease (e.g., a hyperproliferative disease or a catabolic cancer). In some examples, the hyperproliferative disease is cancer. In some examples, the cancer is a solid tumor or a metastatic form thereof. In some examples, the cancer is a blood cancer, e.g., leukemia or lymphoma.
[0250] In some examples, the subject has cancer or is at risk of having cancer. For example, in some examples, the subject has a genetic predisposition to cancer (e.g., having a genetic mutation that increases the baseline risk for developing cancer). In some examples, the subject has been exposed to an environmental perturbation (e.g., radiation or chemicals) that increases the risk of developing cancer. In some examples, the subject needs to be monitored for the development of cancer. In some examples, the subject needs to be monitored for progression or regression of cancer, for example, after being treated with an anti-cancer therapy (or anti-cancer treatment). In some examples, the subject needs to be monitored for recurrence of cancer. In some examples, the subject needs to be monitored for minimal residual disease (MRD). In some examples, the subject has been or is being treated for cancer. In some examples, the subject has not been treated with an anti-cancer therapy (or anti-cancer treatment).
[0251] In some instances, a subject (e.g., a patient) is being treated or has previously been treated with one or more targeted therapies. In some instances, for example, for a patient who has previously been treated with a targeted therapy, a post-targeted therapy sample (e.g., specimen) is obtained (e.g., collected). In some instances, a post-targeted therapy sample is a sample obtained after completion of the targeted therapy.
[0252] In some instances, the patient has not been previously treated with a targeted therapy. In some instances, e.g., for patients who have not been previously treated with a targeted therapy, the sample includes a resection, e.g., the original resection, or a resection following a recurrence (e.g., following disease recurrence following treatment).
[0253] cancer In some examples, the sample is obtained from a subject with cancer. Exemplary cancers include, but are not limited to, B-cell cancer (e.g., multiple myeloma), melanoma, breast cancer, lung cancer (such as non-small cell lung cancer or NSCLC), bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, and the like. Cancer of the small intestine or adnexa, cancer of the salivary gland, thyroid cancer, adrenal adenocarcinoma, osteosarcoma, chondrosarcoma, cancer of the blood tissue, adenocarcinoma, inflammatory myofibroblastic tumor, gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma (NHL), soft tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelial sarcoma, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder cancer, epithelial carcinoma, glioma, astrocytic These include medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, essential thrombocythemia, agnogenic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familial hypereosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, and carcinoma-like tumors.
[0254] In some examples, the cancer is a hematological malignancy (or pre-malignancy). As used herein, hematological malignancy refers to a tumor of hematopoietic or lymphatic tissue, e.g., a tumor affecting the blood, bone marrow, or lymph nodes. Exemplary hematological malignancies include leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, acute monocytic leukemia (AMoL), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), or large granular lymphocytic leukemia), lymphoma (e.g., AIDS-related lymphoma, cutaneous T-cell lymphoma, Hodgkin's lymphoma (e.g., classical Hodgkin's lymphoma or nodal lymphocytic predominant), and / or pulmonary leukemia (PCL). Hodgkin's lymphoma), mycosis fungoides, non-Hodgkin's lymphoma (e.g., B-cell non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma, small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, or mantle cell lymphoma) or T-cell non-Hodgkin's lymphoma (mycosis fungoides, anaplastic large cell lymphoma, or precursor T-lymphoblastic lymphoma)), primary central nervous system.
[0255] Nucleic Acid Extraction and Processing DNA or RNA can be extracted from tissue samples, biopsy samples, blood samples, or other bodily fluid samples using any of a variety of techniques known to those of skill in the art (see, e.g., Example 1 of International Patent Application Publication No. WO 2012 / 092426; Tan, et al. (2009), "DNA, RNA, and Protein Extraction: The Past and The Present", J. Biomed. Biotech. 2009:574398; the technical literature for the Maxwell® 16 LEV Blood DNA Kit (Promega Corporation, Madison, WI); and the Maxwell 16 Buccal Swab LEV DNA Purification Kit Technical Manual (Promega Literature #TM333, January 1, 2011, Promega Corporation, Madison, WI)). Protocols for RNA isolation are disclosed, for example, in the Maxwell® 16 Total RNA Purification Kit Technical Bulletin (Promega Literature #TB351, August 2009, Promega Corporation, Madison, WI).
[0256] A typical DNA extraction procedure includes, for example, (i) collection of a fluid, cell, or tissue sample from which DNA is to be extracted; (ii) if necessary, disruption of cell membranes to release DNA and other cytoplasmic components (i.e., cell lysis); (iii) treatment of the liquid or lysed sample with a concentrated salt solution to precipitate proteins, lipids, and RNA, followed by centrifugation to separate the precipitated proteins, lipids, and RNA; and (iv) purification of the DNA from the supernatant to remove detergents, proteins, salts, or other reagents used during the cell membrane lysis step.
[0257] Disruption of cell membranes can be performed using a variety of mechanical shearing (e.g., French press or fine needle) or ultrasonic disruption techniques. The cell lysis step often involves the use of detergents and surfactants to dissolve lipid, cell and nuclear membranes. In some instances, the lysis step may further include the use of proteases to break down proteins and / or RNases to digest RNA in the sample.
[0258] Examples of suitable techniques for DNA purification include, but are not limited to, (i) precipitation in ice-cold ethanol or isopropanol followed by centrifugation (which may be enhanced by increasing the ionic strength, e.g., by adding sodium acetate, to precipitate the DNA); (ii) phenol-chloroform extraction followed by centrifugation to separate the aqueous phase containing the nucleic acids from the organic phase containing the denatured proteins; and (iii) solid-phase chromatography, in which the nucleic acids are adsorbed to a solid phase (e.g., silica or other) depending on the pH and salt concentration of the buffer.
[0259] In some instances, cellular and histone proteins bound to DNA can be removed by adding proteases or by precipitating the proteins with sodium acetate or ammonium acetate, or through extraction with a phenol-chloroform mixture prior to the DNA precipitation step.
[0260] In some instances, DNA may be extracted using any of a variety of suitable commercially available DNA extraction and purification kits, including, but not limited to, the QIAamp (for isolating genomic DNA from human samples) and DNAeasy (for isolating genomic DNA from animal or plant samples) kits from Qiagen (Germantown, MD), or the Maxwell® and ReliaPrep™ series from Promega (Madison, WI).
[0261] As noted above, in some examples, the sample may include a formalin-fixed (or formaldehyde-fixed, or paraformaldehyde-fixed), paraffin-embedded (FFPE) tissue preparation. For example, an FFPE sample may be a tissue sample embedded in a matrix, such as an FFPE block. Methods for isolating nucleic acids (e.g., DNA) from formaldehyde-fixed or paraformaldehyde-fixed, paraffin-embedded (FFPE) tissues are described, for example, in Cronin, et al., (2004) Am J Pathol. 164(1):35-42; Masuda, et al., (1999) Nucleic Acids Res. 27(22):4436-4443; Specht, et al., (2001) Am J Pathol. 158(2):419-429; Ambion RecoverAll™ Total Nucleic Acid Isolation Protocol (Ambion, Cat. No. AM1975, September 2008); Maxwell® 16 FFPE Plus LEV DNA Purification Kit Technical Manual (Promega Literature #TM349, February 2011); EZNA® FFPE DNA Kit Handbook (OMEGA bio-tek, Norcross, GA, product numbers D3399-00, D3399-01, and D3399-02, June 2009), as well as the QIAamp® DNA FFPE Tissue Handbook (Qiagen, Cat. No. 37625, October 2007). For example, the RecoverAll™ Total Nucleic Acid Isolation Kit uses xylene at high temperature to solubilize paraffin-embedded samples and captures nucleic acids through glass fiber filters. The Maxwell® 16 FFPE Plus LEV DNA Purification Kit is used with the Maxwell® 16 Instrument to purify genomic DNA from 1 to 10 μm sections of FFPE tissue.DNA is purified using silica-clad paramagnetic particles (PMPs) and eluted in low elution volumes. The EZNA® FFPE DNA Kit uses spin columns and a buffer system for isolation of genomic DNA. The QIAamp® DNA FFPE Tissue Kit uses QIAamp® DNA Micro technology for purification of genomic and mitochondrial DNA.
[0262] In some examples, the disclosed methods may further include determining or obtaining a yield value of the nucleic acid extracted from the sample and comparing the determined value to a reference value. For example, if the determined or obtained value is less than the reference value, the nucleic acid may be amplified before proceeding with library construction. In some examples, the disclosed methods may further include determining or obtaining a value for the size (or average size) of the nucleic acid fragments in the sample and comparing the determined or obtained value to a reference value, for example, a size (or average size) of at least 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 base pairs (bps). In some examples, one or more parameters described herein may be adjusted or selected in response to this determination.
[0263] After isolation, the nucleic acid is typically dissolved in a slightly alkaline buffer, such as Tris-EDTA (TE) buffer, or in ultrapure water. In some examples, the isolated nucleic acid (e.g., genomic DNA) can be fragmented or sheared by using any of a variety of techniques known to those skilled in the art. For example, genomic DNA can be fragmented by physical shearing, enzymatic cleavage, chemical cleavage, and other methods known to those skilled in the art. Methods for DNA shearing are described, for example, in Example 4 of International Patent Application Publication No. 2012 / 092426. In some examples, alternative methods of DNA shearing can be used to avoid the ligation step during library preparation.
[0264] Library preparation In some examples, the nucleic acids isolated from the sample can be used to construct a library (e.g., a nucleic acid library described herein). In some examples, the nucleic acids are fragmented using any of the methods described above, optionally subjected to repair of strand end damage, optionally ligated to synthesize adapters, primers, and / or barcodes (e.g., amplification primers, sequencing adapters, flow cell adapters, substrate adapters, sample barcodes or indexes, and / or unique molecular identifier sequences), size selected (e.g., by preparative gel electrophoresis), and / or amplified (e.g., using PCR, non-PCR amplification techniques, or isothermal amplification techniques). In some examples, the fragmented and adapter-ligated nucleic acid population is used without explicit size selection or amplification prior to hybridization-based selection of target sequences. In some examples, the nucleic acids are amplified by any of a variety of specific or non-specific nucleic acid amplification methods well known to those of skill in the art. In some examples, the nucleic acids are amplified by whole genome amplification methods, such as, for example, random primed strand displacement amplification. Examples of nucleic acid library preparation techniques for next-generation sequencing are described, for example, in van Dijk, et al. (2014), Exp. Cell Research 322:12-20, and Illumina's genomic DNA sample preparation kit.
[0265] In some examples, the resulting nucleic acid library may contain all or substantially all of the complexity of the genome. The term "substantially all" in this context actually refers to the possibility that there may be some undesired loss of genome complexity during the initial steps of the procedure. The methods described herein are also useful when the nucleic acid library is a portion of a genome, for example, when the complexity of the genome is reduced by design. In some examples, any selected portion of the genome may be used with the methods described herein. For example, in certain embodiments, the entire exome or a subset thereof is isolated. In some examples, the library may contain at least 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% genomic DNA. In some examples, the library may consist of cDNA copies of genomic DNA that contain at least 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% genomic DNA. In certain examples, the amount of nucleic acid used to generate a nucleic acid library can be less than 5 micrograms, less than 1 microgram, less than 500 ng, less than 200 ng, less than 100 ng, less than 50 ng, less than 10 ng, less than 5 ng, or less than 1 ng.
[0266] In some examples, a library (e.g., a nucleic acid library) comprises a collection of nucleic acid molecules. As described herein, the nucleic acid molecules of the library can include target nucleic acid molecules (e.g., tumor nucleic acid molecules, reference nucleic acid molecules, and / or control nucleic acid molecules, also referred to herein as first, second, and / or third nucleic acid molecules, respectively). The nucleic acid molecules of the library can be derived from a single subject or individual. In some examples, a library can include nucleic acid molecules from two or more subjects (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30 or more subjects). For example, two or more libraries from different subjects can be combined to form a library with nucleic acid molecules from two or more subjects (wherein the nucleic acid molecules from each subject are optionally ligated to a unique sample barcode corresponding to the particular subject). In some examples, the subjects are humans who have or are at risk of having cancer or a tumor.
[0267] In some examples, a library (or a portion thereof) may include one or more subgenomic intervals. In some examples, a subgenomic interval may be a single nucleotide position, e.g., a nucleotide position where a variant at that position is associated (positively or negatively) with a tumor phenotype. In some examples, a subgenomic interval includes two or more nucleotide positions. Such examples include a sequence of at least 2, 5, 10, 50, 100, 150, 250, or more than 250 nucleotide positions in length. A subgenomic interval may include, for example, one or more entire genes (or portions thereof), one or more exons or coding sequences (or portions thereof), one or more introns (or portions thereof), one or more microsatellite regions (or portions thereof), or any combination thereof. A subgenomic interval may include all or a portion of a fragment of a naturally occurring nucleic acid molecule, e.g., a genomic DNA molecule. For example, a subgenomic interval may correspond to a fragment of genomic DNA that is subjected to a sequencing reaction. In some examples, a subgenomic interval is a contiguous sequence from a genomic source. In some instances, the subgenomic interval comprises sequences that are not contiguous in the genome, for example, a subgenomic interval in a cDNA may comprise an exon-exon junction formed as a result of splicing. In some instances, the subgenomic interval comprises a tumor nucleic acid molecule. In some instances, the subgenomic interval comprises a non-tumor nucleic acid molecule.
[0268] Targeting loci for analysis The methods described herein may be used in combination with, or as part of, a method for evaluating a set of intervals of interest (e.g., target sequences) from, for example, a set of genomic loci (e.g., loci or fragments thereof), as described herein.
[0269] In some examples, the set of genomic loci evaluated by the disclosed methods includes multiple, e.g., genes, that, in mutant form, are associated with an effect on cell division, proliferation or survival, or are associated with cancer, e.g., a cancer described herein.
[0270] In some examples, the set of loci evaluated by the disclosed methods includes at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, or more than 100 loci.
[0271] In some examples, the selected locus (also referred to herein as a target locus or target sequence) or a fragment thereof may comprise an interval of interest, including a non-coding sequence, a coding sequence, an intragenic region, or an intergenic region of the genome of interest. For example, the interval of interest may include a non-coding sequence or a fragment thereof (e.g., a promoter sequence, an enhancer sequence, a 5' untranslated region (5'UTR), a 3' untranslated region (3'UTR), or a fragment thereof), a coding sequence of a fragment thereof, an exon sequence or a fragment thereof, an intron sequence or a fragment thereof.
[0272] Target Capture Reagents The methods described herein may include contacting a nucleic acid library with a plurality of target capture reagents to select and capture a plurality of specific target sequences (e.g., gene sequences or fragments thereof) for analysis. In some examples, a target capture reagent (i.e., a molecule that binds to a target molecule, thereby allowing capture of the target molecule) is used to select the interval of interest to be analyzed. For example, the target capture reagent may be a bait molecule, e.g., a nucleic acid molecule (e.g., a DNA molecule or an RNA molecule), that can hybridize to (i.e., be complementary to) a target molecule, thereby allowing capture of the target nucleic acid. In some examples, the target capture reagent, e.g., a bait molecule (or bait sequence), is a capture oligonucleotide (or capture probe). In some examples, the target nucleic acid is a genomic DNA molecule, an RNA molecule, a cDNA molecule derived from an RNA molecule, a microsatellite DNA sequence, or the like. In some examples, the target capture reagent is suitable for solution-phase hybridization to the target. In some examples, the target capture reagent is suitable for solid-phase hybridization to the target. In some instances, the target capture reagent is suitable for both solution phase and solid phase hybridization to the target. The design and construction of target capture reagents is described in more detail, for example, in International Patent Application Publication No. WO 2020 / 236941, the entire contents of which are incorporated herein by reference.
[0273] The methods described herein provide optimized sequencing of multiple genomic loci (e.g., genes or gene products (e.g., mRNA), microsatellite loci, etc.) from samples (e.g., cancer tissue specimens, liquid biopsy samples, etc.) from one or more subjects by appropriate selection of target capture reagents to select the target nucleic acid molecules to be sequenced. In some examples, a target capture reagent may hybridize to a specific target locus, e.g., a specific target locus or fragment thereof. In some examples, a target capture reagent may hybridize to a specific group of target loci, e.g., a specific group of loci or fragments thereof. In some examples, multiple target capture reagents may be used, including a mix of target-specific and / or group-specific target capture reagents.
[0274] In some examples, the number of target capture reagents (e.g., bait molecules) in a plurality of target capture reagents (e.g., bait set) contacted with a nucleic acid library to capture a plurality of target sequences for nucleic acid sequencing is greater than 10, greater than 50, greater than 100, greater than 200, greater than 300, greater than 400, greater than 500, greater than 600, greater than 700, greater than 800, greater than 900, greater than 1,000, greater than 1,250, greater than 1,500, greater than 1,750, greater than 2,000, greater than 3,000, greater than 4,000, greater than 5,000, greater than 10,000, greater than 25,000, or greater than 50,000.
[0275] In some examples, the total length of the target capture reagent sequence can be between about 70 nucleotides and 1000 nucleotides. In one example, the length of the target capture reagent is between about 100 and 300 nucleotides, between 110 and 200 nucleotides, or between 120 and 170 nucleotides in length. In addition to the above, intermediate oligonucleotide lengths of about 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 300, 400, 500, 600, 700, 800, and 900 nucleotides in length can be used in the methods described herein. In some embodiments, oligonucleotides of about 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220 or 230 bases can be used.
[0276] In some examples, each target capture reagent sequence may include (i) a target-specific capture sequence (e.g., a locus- or microsatellite locus-specific complementary sequence), (ii) an adapter, primer, barcode, and / or unique molecular identifier sequence, and (iii) a universal tail at one or both ends. As used herein, the term "target capture reagent" may refer to a target-specific target capture sequence or an entire target capture reagent oligonucleotide that includes a target-specific target capture sequence.
[0277] In some examples, the target-specific capture sequence in the target capture reagent is about 40 nucleotides to 1000 nucleotides in length. In some examples, the target-specific capture sequence is about 70 nucleotides to 300 nucleotides in length. In some examples, the target-specific sequence is about 100 nucleotides to 200 nucleotides in length. In still other examples, the target-specific sequence is about 120 nucleotides to 170 nucleotides in length, typically 120 nucleotides in length. In addition to the above, target-specific sequences of intermediate lengths, for example, about 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 300, 400, 500, 600, 700, 800, and 900 nucleotides in length, as well as target-specific sequences of lengths between the above lengths, can also be used in the methods described herein.
[0278] In some examples, target capture reagent can be designed to select the target section that contains one or more rearrangements, for example, the intron that contains genomic rearrangement.In such examples, target capture reagent is designed to mask repetitive sequences to improve selection efficiency.In these examples where rearrangement has known linking sequence, complementary target capture reagent can be designed to linking sequence to improve selection efficiency.
[0279] In some examples, the disclosed methods may include the use of target capture reagents designed to capture two or more different target categories, with each category having a different target capture reagent design strategy. In some examples, the hybridization-based capture methods and target capture reagent compositions disclosed herein provide capture and homogenous coverage of a target sequence set, while minimizing coverage of genomic sequences outside the targeted sequence set. In some examples, the target sequences may include entire exomes of genomic DNA or selected subsets thereof. In some examples, the target sequences may include, for example, large chromosomal regions (e.g., entire chromosomal arms). The methods and compositions disclosed herein provide different target capture reagents to achieve different sequencing depths and coverage patterns for a complex target nucleic acid sequence set.
[0280] Typically, DNA molecules are used as target capture reagent sequences, but RNA molecules can also be used. In some instances, DNA molecule target capture reagents can be single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA). In some instances, RNA-DNA duplexes are more stable than DNA-DNA duplexes, and therefore potentially provide better capture of nucleic acids.
[0281] In some examples, the disclosed methods include providing a selected set of nucleic acid molecules (e.g., library catch) captured from one or more nucleic acid libraries. For example, the methods can include providing one or more nucleic acid libraries, each containing a plurality of nucleic acid molecules (e.g., a plurality of target nucleic acid molecules and / or reference nucleic acid molecules) extracted from one or more samples from one or more subjects, contacting the one or more libraries (e.g., in a solution-based hybridization reaction) with one, two, three, four, five, or more than five target capture reagents (e.g., oligonucleotide target capture reagents) to form a hybridization mixture containing a plurality of target capture reagent / nucleic acid molecule hybrids, and separating the plurality of target capture reagent / nucleic acid molecule hybrids from the hybridization mixture, e.g., by contacting the hybridization mixture with a binding entity that allows separation of the plurality of target capture reagent / nucleic acid molecule hybrids from the hybridization mixture, thereby providing a library catch (e.g., a subgroup of selected or enriched nucleic acid molecules from one or more libraries).
[0282] In some examples, the disclosed methods can further include amplifying the library catch (e.g., by performing PCR). In other examples, the library catch is not amplified.
[0283] In some examples, the target capture reagent may be part of a kit, which may include instructions, standards, buffers or enzymes or other reagents as needed.
[0284] Hybridization conditions As noted above, the methods disclosed herein can include contacting a library (e.g., a nucleic acid library) with a plurality of target capture reagents to contact selected library target nucleic acid sequences (i.e., library catch). The contacting step can be performed, for example, by solution-based hybridization. In some examples, the method includes repeating the hybridization step for one or more additional solution-based hybridizations. In some examples, the method further includes subjecting the library catch to one or more additional solution-based hybridizations with the same or a different set of target capture reagents.
[0285] In some examples, the contacting step is performed using a solid support, e.g., an array. Suitable solid supports for hybridization are described, for example, in Albert, TJ et al. (2007) Nat. Methods 4(11):903-5, Hodges, E. et al. (2007) Nat. Genet. 39(12):1522-7, and Okou, DT et al. (2007) Nat. Methods 4(11):907-9, the contents of which are incorporated herein by reference in their entirety.
[0286] Hybridization methods that can be adapted for use in the methods herein are described in the art, for example, as described in International Patent Application Publication No. 2012 / 092426. Methods for hybridizing target capture reagents to multiple target nucleic acids are described in more detail, for example, in International Patent Application Publication No. 2020 / 236941, the entire contents of which are incorporated herein by reference.
[0287] Sequencing methods The methods and systems disclosed herein may be used in conjunction with or as part of a method or system for sequencing nucleic acids (e.g., a next-generation sequencing system) to generate multiple sequence reads that overlap one or more loci within a subgenomic interval in a sample, thereby, for example, determining gene allele sequences at multiple loci. As used herein, "next-generation sequencing" (or "NGS") may also be referred to as "massively parallel sequencing" and refers to any sequencing method that determines the nucleotide sequence of individual nucleic acid molecules (e.g., in single-molecule sequencing) or clonally expanded proxies of individual nucleic acid molecules in a high-throughput manner (e.g., 10, 10, 10, or more than 10 molecules are sequenced simultaneously).
[0288] Next generation sequencing methods are known in the art and are described, for example, in Metzker, M. (2010) Nature Biotechnology Reviews 11:31-46, which is incorporated herein by reference. Other examples of sequencing methods suitable for use in implementing the methods and systems disclosed herein are described, for example, in International Patent Application Publication No. 2012 / 092426. In some examples, sequencing may include, for example, whole genome sequencing (WGS), whole exome sequencing, targeted sequencing, or direct sequencing. In some examples, sequencing may be performed using, for example, Sanger sequencing. In some examples, sequencing may include paired-end sequencing techniques that allow both ends of a fragment to be sequenced and generate high quality alignable sequence data for, for example, detection of genomic rearrangements, repetitive sequence elements, gene fusions, and novel transcripts.
[0289] The disclosed methods and systems may be implemented using a sequencing platform, such as Roche 454, Illumina Solexa, ABI-SOLiD, ION Torrent, Complete Genomics, Pacific Bioscience, Helicos, and / or Polonator platforms. In some examples, the sequencing may include Illumina MiSeq sequencing. In some examples, the sequencing may include Illumina HiSeq sequencing. In some examples, the sequencing may include Illumina NovaSeq sequencing. Optimized methods for sequencing multiple target genomic loci in nucleic acid extracted from a sample are described in more detail, for example, in International Patent Application Publication No. WO 2020 / 236941, the entire contents of which are incorporated herein by reference.
[0290] In certain examples, the disclosed methods include the steps of: (a) obtaining a library from a sample comprising a plurality of normal and / or tumor nucleic acid molecules; (b) simultaneously or sequentially contacting the library with a plurality of 1, 2, 3, 4, 5, or more than 5 target capture reagents under conditions that allow hybridization of the target capture reagents to the target nucleic acid molecules, thereby providing a selected set of captured normal and / or tumor nucleic acid molecules (i.e., library catch); and (c) hybridizing the selected subset of nucleic acid molecules (e.g., library catch) by, for example, contacting the hybridization mixture with a binding entity that allows separation of the target capture reagent / nucleic acid molecule hybrids from the hybridization mixture. (d) sequencing the library catch to obtain a plurality of reads (e.g., sequence reads) that overlap with one or more intervals of interest (e.g., one or more target sequences) from the library catch, which may contain mutations (or alterations), e.g., variant sequences that contain somatic or germline mutations; (e) aligning the sequence reads using an alignment method described elsewhere herein; and / or (f) assigning nucleotide values to nucleotide positions within the intervals of interest from one or more sequence reads of the plurality (e.g., calling mutations, e.g., using a Bayesian method or other method described herein).
[0291] In some examples, obtaining sequence reads for one or more intervals of interest may include sequencing at least 1, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 550, at least 600, at least 650, at least 700, at least 750, at least 800, at least 850, at least 900, at least 950, at least 1,000, at least 1,250, at least 1,500, at least 1,750, at least 2,000, at least 2,250, at least 2,500, at least 2,750, at least 3,000, at least 3,500, at least 4,000, at least 4,500, or at least 5,000 loci, e.g., genomic loci, loci, microsatellite loci, etc. In some examples, obtaining sequence reads for one or more target intervals can include sequencing the target intervals for any number of loci within the ranges described in this paragraph, for example, at least 2,850 loci.
[0292] In some examples, obtaining sequence reads for one or more intervals of interest includes sequencing the intervals of interest using a sequencing method that provides a sequence read length (or average sequence read length) of at least 20 bases, at least 30 bases, at least 40 bases, at least 50 bases, at least 60 bases, at least 70 bases, at least 80 bases, at least 90 bases, at least 100 bases, at least 120 bases, at least 140 bases, at least 160 bases, at least 180 bases, at least 200 bases, at least 220 bases, at least 240 bases, at least 260 bases, at least 280 bases, at least 300 bases, at least 320 bases, at least 340 bases, at least 360 bases, at least 380 bases, or at least 400 bases. In some examples, obtaining sequence reads for one or more intervals of interest can include sequencing the intervals of interest using a sequencing method that provides a sequence read length (or average sequence read length) of any number of bases within the ranges described in this paragraph, for example, a sequence read length (or average sequence read length) of 56 bases.
[0293] In some examples, obtaining sequence reads for one or more target intervals may include sequencing at an average coverage (or depth) of at least 100x or more. In some examples, obtaining sequence reads for one or more target intervals may include sequencing at an average coverage (or depth) of at least 100x, at least 150x, at least 200x, at least 250x, at least 500x, at least 750x, at least 1,000x, at least 1,500x, at least 2,000x, at least 2,500x, at least 3,000x, at least 3,500x, at least 4,000x, at least 4,500x, at least 5,000x, at least 5,500x, or at least 6,000x or more. In some examples, obtaining sequence reads for one or more target intervals may include sequencing at an average coverage (or depth) having any value within the range of values described in this paragraph, for example, at least 160x.
[0294] In some examples, obtaining sequence reads for one or more target intervals includes sequencing at an average sequencing depth having any value ranging from at least 100x to at least 6,000x for more than about 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% of the sequenced loci. For example, in some examples, obtaining reads for a target interval includes sequencing at an average sequencing depth of at least 125x for at least 99% of the sequenced loci. As another example, in some examples, obtaining reads for a target interval includes sequencing at an average sequencing depth of at least 4,100x for at least 95% of the sequenced loci.
[0295] In some examples, the relative abundance of nucleic acid species in a library can be estimated by counting the relative number of occurrences of their cognate sequences in the data generated by the sequencing experiment (e.g., the number of sequence reads for a given cognate sequence).
[0296] In some examples, the disclosed methods and systems provide nucleotide sequences for a set of subject intervals (e.g., loci) as described herein. In certain instances, the sequences are provided without the use of methods that include matched normal controls (e.g., wild-type controls) and / or matched tumor controls (e.g., primary vs. metastatic).
[0297] In some examples, as used herein, the level of sequencing depth (e.g., X-fold level of sequencing depth) refers to the number of reads (e.g., unique reads) obtained after detection and removal of duplicate reads (e.g., PCR duplicate reads). In other examples, duplicate reads are evaluated, for example, to aid in the detection of copy number alterations (CNAs).
[0298] alignment Alignment is the process of matching reads to a location, such as a genomic location or locus. In some examples, NGS reads can be aligned to a known reference sequence (e.g., a wild-type sequence). In some examples, NGS reads can be de novo assembled. Methods of sequence alignment for NGS reads are described, for example, in Trapnell, C. and Salzberg, SL Nature Biotech., 2009, 27:455-457. Examples of de novo sequence assembly are described, for example, in Warren R. et al., Bioinformatics, 2007, 23:500-501, Butler J. et al., Genome Res., 2008, 18:810-820, and Zerbino DR and Birney E., Genome Res., 2008, 18:821-829. Optimization of sequence alignment is described in the art, for example, as described in International Patent Application Publication No. 2012 / 092426. Additional descriptions of sequence alignment methods are described in more detail, for example, in International Patent Application Publication No. 2020 / 236941, the entire contents of which are incorporated herein by reference.
[0299] Misalignment (e.g., placement of base pairs from short reads at incorrect locations in the genome), for example, misalignment of reads due to sequence context (e.g., presence of repetitive sequences) around the actual cancer mutation can lead to reduced sensitivity of mutation detection because alternate allele reads can be shifted from the histogram peak of alternate allele reads. Other examples of sequence contexts that can cause misalignment include short tandem repeats, interspersed repetitive sequences, low complexity regions, insertion-deletions (indels), and paralogs. When problematic sequence situations arise in the absence of actual mutations, misalignment can introduce artifactual reads of "mutated" alleles by misplacing reads of the actual reference genome base sequence. Because mutation calling algorithms for multigene analysis must be sensitive to even low abundance mutations, sequence misalignment can increase false positive discovery rates and / or reduce specificity.
[0300] In some examples, the methods and systems disclosed herein may integrate the use of multiple individually tailored alignment methods or algorithms to optimize base calling performance in sequencing methods, particularly those that rely on massively parallel sequencing of multiple diverse genetic events at multiple diverse genomic loci. In some examples, the disclosed methods and systems may include the use of one or more global alignment algorithms. In some examples, the disclosed methods and systems may include the use of one or more local alignment algorithms.Examples of alignment algorithms that may be used include, but are not limited to, the Burrows-Wheeler Alignment (BWA) software bundle (see, e.g., Li, et al. (2009), "Fast and Accurate Short Read Alignment with Burrows-Wheeler Transform", Bioinformatics 25:1754-60; Li, et al. (2010), Fast and Accurate Long-Read Alignment with Burrows-Wheeler Transform", Bioinformatics epub. PMID:20080505), the Smith-Waterman algorithm (see, e.g., Smith, et al. (1981), "Identification of Common Molecular Subsequences", J. Molecular Biology 147(1):195-197), the Striped Smith-Waterman algorithm (see, e.g., Farrar (2007), "Striped Smith-Waterman Speeds Database Searches Six Times Over Other SIMD Examples of such algorithms include the Needleman-Wunsch algorithm (see, for example, "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", J. Molecular Biology 48(3):443-53), or any combination thereof.
[0301] In some examples, the methods and systems disclosed herein may also include the use of a sequence assembly algorithm, such as the Arachne sequencing assembly algorithm (see, e.g., Batzoglou, et al. (2002), "ARACHNE: A Whole-Genome Shotgun Assembler", Genome Res. 12:177-189).
[0302] In some examples, the alignment method used to analyze the sequence reads is not individually customized or adjusted for the detection of different variants (e.g., point mutations, insertions, deletions, etc.) at different genomic loci. In some examples, different alignment methods are used to analyze the reads that are individually customized or adjusted for the detection of at least a subset of the different variants detected at different genomic loci. In some examples, different alignment methods are used to analyze the reads that are individually customized or adjusted for the detection of each different variant at different genomic loci. In some examples, the adjustments can be a function of one or more of: (i) the locus to be sequenced (e.g., a gene locus, a microsatellite locus, or other interval of interest), (ii) the tumor type associated with the sample, (iii) the variant to be sequenced, or (iv) the characteristics of the sample or subject. The selection or use of alignment conditions that are individually adjusted to several specific intervals of interest to be sequenced allows for the optimization of speed, sensitivity, and specificity. This method is particularly effective when the alignment of reads to a relatively large number of diverse intervals of interest is optimized. In some instances, the methods include the use of an alignment method optimized for the rearrangement in combination with another alignment method optimized for a target interval not associated with the rearrangement.
[0303] In some examples, the methods disclosed herein further include selecting or using an alignment method for analyzing, e.g., aligning, the sequence reads, where the alignment method is a function of, selected in response to, or optimized for one or more of: (i) the tumor type, e.g., the tumor type in the sample; (ii) the location (e.g., locus) of the interval of interest to be sequenced; (iii) the type of variant (e.g., point mutation, insertion, deletion, substitution, copy number variation (CNV), rearrangement, or fusion) within the interval of interest to be sequenced; (iv) the site (e.g., nucleotide position) being analyzed; (v) the type of sample (e.g., a sample described herein); and / or (vi) the flanking sequences within or near the interval of interest being evaluated (e.g., according to their expected propensity for misalignment of the interval of interest due, e.g., to the presence of repetitive sequences within or near the interval of interest).
[0304] In some examples, the methods disclosed herein allow for fast and efficient alignment of troublesome reads, e.g., reads with rearrangements.Thus, in some examples where the reads for the target interval include nucleotide positions with rearrangements, e.g., translocations, the method can include using an alignment method that is appropriately adjusted and includes: (i) selecting a rearrangement reference sequence for alignment with the read, where the rearrangement reference sequence aligns with the rearrangement (in some examples, the reference sequence is not identical to the genomic rearrangement), and (ii) comparing, e.g., aligning, the read with the rearrangement reference sequence.
[0305] In some examples, alternative methods can be used to align problematic reads. These methods are particularly effective when alignment of reads to a relatively large number of diverse target intervals is optimized. As an example, a method of analyzing a sample can include (i) performing a comparison (e.g., alignment comparison) of reads using a first set of parameters (e.g., using a first mapping algorithm or by comparison with a first reference sequence) to determine whether the reads meet a first alignment criterion (e.g., the reads can be aligned with the first reference sequence, e.g., with less than a certain number of mismatches); and (ii) performing a second alignment comparison using a second set of parameters if the reads do not meet the first alignment criterion (e.g., performing a second alignment comparison). (e.g., using a mapping algorithm or by comparison to a second reference sequence); and (iii) optionally determining whether the read satisfies a second criterion (e.g., the read can be aligned with the second reference sequence, e.g., with less than a certain number of mismatches), including use of the second reference sequence, where the second parameter set is more likely to result in alignment of the read to a variant (e.g., a rearrangement, insertion, deletion, or translocation), e.g., compared to the first parameter set.
[0306] In some examples, alignment of sequence reads in the disclosed methods may be combined with mutation calling methods described elsewhere herein. As discussed herein, reduced sensitivity for detecting actual mutations may be addressed by assessing (manually or in an automated manner) the quality of the alignment around the expected mutation site of the gene or genomic locus (e.g., locus) being analyzed. In some examples, the site to be assessed may be obtained from a database of human genomes (e.g., HG19 human reference genome) or cancer mutations (e.g., COSMIC). Regions identified as problematic may be repaired, for example, by alignment optimization (or realignment) using a slower but more accurate alignment algorithm such as Smith-Waterman alignment, using an algorithm selected to give better performance in the relevant sequence context. If general alignment algorithms are unable to ameliorate the problem, customized alignment approaches can be created by, for example, adjusting the maximum different mismatch penalty parameters for genes that are likely to contain substitutions, adjusting specific mismatch penalty parameters based on specific mutation types that are common to particular tumor types (e.g., C□T in melanoma), or adjusting specific mismatch penalty parameters based on specific mutation types that are common to a particular sample type (e.g., substitutions that are common to FFPE).
[0307] The loss of specificity (increased false positive rate) of the evaluated target interval due to misalignment can be assessed by manual or automated inspection of all variant calls in the sequencing data. Regions found to be prone to false variant calls due to misalignment can be subjected to alignment improvements as discussed above. If algorithmic improvements are not possible, "variations" from problematic regions can be sorted or screened from a panel of target loci.
[0308] Mutation Call A base call refers to the raw output of a sequencing device, e.g., the determined sequence of nucleotides in an oligonucleotide molecule. A variant call refers to the process of selecting a nucleotide value, e.g., A, G, T, or C, for a given nucleotide position being sequenced. Typically, a sequence read (or base call) for a position will provide more than one value, e.g., some reads will indicate T and some will indicate G. A variant call is the process of assigning the correct nucleotide value, e.g., one of the values, to a sequence. Although referred to as a "variant" call, it can be applied to assign a nucleotide value to any nucleotide position, e.g., a position corresponding to a mutant allele, a wild type allele, an allele not characterized as mutant or wild type, or a position not characterized by variability.
[0309] In some examples, the disclosed methods may include the use of customized or tuned variant calling algorithms or parameters to optimize performance when applied to sequencing data, particularly in methods that rely on massively parallel sequencing of multiple diverse genetic events at multiple diverse genomic loci (e.g., gene loci, microsatellite regions, etc.) in a sample, e.g., from a subject with cancer. Optimization of variant calling has been described in the art, e.g., as described in International Patent Application Publication No. WO 2012 / 092426.
[0310] Methods for variant calling can include one or more of the following: making independent calls based on information at each position in the reference sequence (e.g., examining sequence reads; examining base calls and quality scores; calculating the probability of observed bases and quality scores given potential genotypes; and assigning genotypes (e.g., using Bayes' rule); removing false positives (e.g., using a depth threshold to reject SNPs with read depths much lower or higher than expected; local refinement to remove false positives due to small indels); and performing linkage disequilibrium (LD) / imputation-based analysis to refine the calls.
[0311] The formula used to calculate the genotype likelihood associated with a particular genotype and location is described, for example, in Li H. and Durbin R. Bioinformatics, 2010;26(5):589-95. A priori predictions for a particular mutation in a particular cancer type can be used when evaluating samples from that cancer type. Such probabilities can be obtained from public databases of cancer mutations, such as the Catalogue of Somatic Mutation in Cancer (COSMIC), HGMD (Human Gene Mutation Database), the SNP Consortium, Breast Cancer Mutation Data Base (BIC), and Breast Cancer Gene Database (BCGD).
[0312] Examples of LD / imputation-based analysis are described, for example, in Browning, B. L. and Yu, Z. Am. J. Hum. Genet. 2009, 85(6):847-61. Examples of low coverage SNP calling methods are described, for example, in Li, Y., et al., Annu. Rev. Genomics Hum. Genet. 2009, 10:387-406.
[0313] After alignment, detection of substitutions can be performed using a mutation calling method (e.g., a Bayesian mutation calling method), which is applied to each base in each of the target intervals, e.g., exons of the gene or other locus being evaluated, and the presence of alternative alleles is observed. This method compares the probability of observing read data in the presence of a mutation to the probability of observing read data in the presence of base calling errors alone. If this comparison is sufficiently strong in support of the presence of a mutation, the mutation can be called.
[0314] The advantage of a Bayesian mutation detection approach is that the comparison of the probability of the presence of a mutation versus the probability of a base calling error alone can be weighted by a prior expectation of the presence of the mutation at that site. If several reads of alternative alleles are observed at a site that is frequently mutated for a given cancer type, the presence of the mutation can be called with confidence even if the amount of evidence for the mutation does not meet the usual threshold. This flexibility can then be used to increase the detection sensitivity for rarer mutations / lower purity samples or to make the test more robust against reduced read coverage. The likelihood of a random base pair in the genome being mutated in cancer is approximately 1e-6. For example, the likelihood of a specific mutation occurring at many sites in a typical polygenic cancer genome panel can be orders of magnitude higher. These likelihoods can be derived from public databases of cancer mutations (e.g., COSMIC).
[0315] Indel calling is the process of finding bases in sequencing data that differ from a reference sequence by insertion or deletion, typically with associated confidence score or statistical evidence indicator. Methods of indel calling can include identifying candidate indels, calculating genotype likelihood by local realignment, and performing LD-based genotype inference and calling. Typically, a Bayesian method is used to obtain potential indel candidates, and then these candidates are tested with reference sequences in a Bayesian framework.
[0316] Algorithms for generating candidate indels are described, for example, in McKenna, A., et al., Genome Res. 2010; 20(9): 1297-303, Ye, K., et al., Bioinformatics, 2009; 25(21): 2865-71, Lunter, G., and Goodson, M., Genome Res. 2011; 21(6): 936-9, and Li, H., et al. (2009), Bioinformatics 25(16): 2078-9.
[0317] Methods for generating indel calling and individual-level genotype likelihood include, for example, the Dindel algorithm (Albers CA et al., Genome Res. 2011; 21(6): 961-73). For example, a Bayesian EM algorithm can be used to analyze reads, make initial indel calls, and generate genotype likelihoods for each candidate indel, followed by imputing genotypes using, for example, QCALL (Le SQ and Durbin R. Genome Res. 2011; 21(6): 952-60). Parameters such as prior expectation of observing an indel can be adjusted (e.g., increased or decreased) based on the size or location of the indel.
[0318] Methods have been developed that address limited deviations from 50% or 100% allele frequency for the analysis of cancer DNA. (See, e.g., SNVMix - Bioinformatics. 2010 March 15;26(6):730-736.) However, the methods disclosed herein allow for frequencies (or allele fractions) ranging from 1% to 100% (i.e., allele fractions ranging from 0.01 to 1.0), and in particular, consideration of the possible presence of mutant alleles at levels below 50%. This approach is particularly important for the detection of mutations in, for example, low-purity FFPE samples of native (multiclonal) tumor DNA.
[0319] In some examples, the mutation calling method used to analyze the sequence reads is not individually customized or tuned for the detection of different mutations at different genomic loci. In some examples, a different mutation calling method is used that is individually customized or fine-tuned for at least a subset of the different mutations detected at different genomic loci. In some examples, a different mutation calling method is used that is individually customized or fine-tuned for each different mutation detected at each different genomic locus. The customization or adjustment can be based on one or more of the factors described herein, such as the type of cancer in the sample, the gene or locus in which the target interval to be sequenced is located, or the variant to be sequenced. This selection or use of a mutation calling method that is individually customized or fine-tuned for the number of target intervals to be sequenced allows for optimization of the speed, sensitivity, and specificity of mutation calling.
[0320] In some examples, a nucleotide value is assigned to a nucleotide position of each of the X unique target intervals using a unique variant calling method, where X is at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 1500, at least 2000, at least 2500, at least 3000, at least 3500, at least 4000, at least 4500, at least 5000 or more. The calling methods can be different and thereby unique, for example, by relying on different Bayesian priors.
[0321] In some instances, assigning the nucleotide value is a function of a value that is or represents an expected value prior to observing (e.g., in the literature) reads that exhibit a variant, e.g., mutation, at that nucleotide position in a tumor of the type.
[0322] In some examples, the methods include assigning nucleotide values (e.g., mutation calls) for at least 10, 20, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 nucleotide positions, where each assignment is a function of a unique (as opposed to other assigned values) value that is or represents an expected value prior (e.g., in the literature) of observing reads that indicate a variant, e.g., mutation, at that nucleotide position in a tumor of the type.
[0323] In some examples, assigning the nucleotide value is a function of a set of values that represent the probability of observing a read that exhibits the variant at that nucleotide position if the variant is present in the sample at a particular frequency (e.g., 1%, 5%, 10%, etc.) and / or if the variant is not present (e.g., observed in the read due to base calling errors only).
[0324] In some examples, a mutation calling method described herein may include: (a) obtaining, for a nucleotide position in each of the X intervals of interest, (i) a first value that is or represents an expectation prior to (e.g., literature) observing a read exhibiting a variant, e.g., a mutation, at that nucleotide position in a tumor of type X; and (ii) a second set of values that represent the likelihood of observing a read exhibiting the variant at that nucleotide position if the variant is present in the sample at a certain frequency (e.g., 1%, 5%, 10%, etc.) and / or if the variant is not present (e.g., observed in a read due to base calling error alone); and (b) in response to the values, assigning to each of the nucleotide positions a nucleotide value from the read (e.g., calling a mutation) by weighting a comparison between the values in the second set using the first values (e.g., calculating the posterior probability of the presence of a mutation), e.g., by a Bayesian method described herein, thereby analyzing the sample.
[0325] Further description of the mutation calling method is described in more detail, for example, in International Patent Application Publication No. WO 2020 / 236941, the entire contents of which are incorporated herein by reference.
[0326] Computer-readable medium (software) Any of the foregoing methods of the present disclosure may be implemented as a computer program process specified as a set of instructions recorded on a non-transitory computer readable storage medium (also referred to as computer readable medium - CRM).
[0327] The method provides a non-transitory computer-readable storage medium including one or more programs executed by one or more processors of a device, the one or more programs including instructions that, when executed by the one or more processors, cause the device to implement the method of any one of the preceding embodiments.
[0328] Also provided herein is a non-transitory computer readable storage medium comprising a report generated from performing the method of any one of the preceding embodiments.
[0329] Examples of computer readable storage media include RAM, ROM, read only compact disks (CD-ROMs), recordable compact disks (CD-Rs), rewritable compact disks (CD-RWs), read only digital versatile disks (e.g. DVD-ROMs, dual layer DVD-ROs), various recordable / rewritable DVDs (e.g. DVD-RAMs, DVD-RWs, DVD+RWs, etc.), flash memory (e.g. SD cards, mini-SD cards, micro-SD cards, etc.), magnetic and / or solid state hard drives, ultra-high density optical disks, any other optical or magnetic media, and floppy disks. In some embodiments, the computer readable storage medium is a solid state device, a hard disk, a CD-ROM, or any other non-volatile computer readable storage medium.
[0330] The computer-readable storage medium can store a set of computer-executable instructions (eg, a "computer program") that is executable by at least one processing unit and includes a set of instructions for performing various operations.
[0331] A computer program (also known as a program, software, software application, script, or code) can be written in any form of programming language, including compiled or interpreted languages, declarative or procedural languages, and can be deployed in any form, including as a stand-alone program or as a module, component, or subroutine, object, or other component suitable for use in a computing environment. A computer program may correspond to a file in a file system, but need not. A program can be stored as part of a file that holds other programs or data (e.g., one or more scripts stored in a markup language document), in a single file dedicated to the program in question, or in multiple cooperating files (e.g., files that store one or more modules, subprograms, or portions of code). A computer program can be deployed to be executed on one computer, or on multiple computers located at one site or distributed across multiple sites and interconnected by a communication network. Examples of computer programs or computer code include machine code, such as produced by a compiler, and files containing higher level code that is executed by a computer, electronic component, or microprocessor using an interpreter.
[0332] In some embodiments, software aspects of the disclosure may be implemented as sub-portions of a larger program while remaining separate software aspects of the disclosure. In some implementations, software aspects may also be implemented as separate programs. Any combination of separate programs that together implement the software aspects described herein is within the scope of the disclosure. In some implementations, the software program, when installed to operate on one or more electronic systems, defines one or more specific machine implementations that execute and perform the operations of the software program.
[0333] Electronic Devices and Systems Additionally, any one of the foregoing methods of the present disclosure may be implemented in one or more computer systems or other forms of apparatus, including, but not limited to, computers, tablet personal computers, personal digital assistants, and mobile phones.
[0334] The method provides an electronic device including one or more processors, a memory, and one or more programs, the one or more programs including instructions that, when executed by the one or more processors, cause the device to perform a method according to any one of the preceding embodiments.
[0335] In some embodiments, the electronic device may further include one or more displays. In some embodiments, the electronic device includes one or more displays for presenting a report generated from performing the method of any one of the preceding embodiments.
[0336] In some embodiments, the electronic device may be a server computer, a client computer, a personal computer, a user device, a tablet PC, a laptop computer, a personal digital assistant (PDA), a mobile phone, or any machine capable of executing a set of instructions, sequential or otherwise, that specify actions to be taken by the machine. In some embodiments, the electronic device may further include a keyboard and pointing device, a touch device, a display device, and a network device.
[0337] To provide for user interaction, implementations of the subject matter described herein may be implemented on a computer having a display device described herein for displaying information to a user, a virtual or physical keyboard, and a pointing device such as a finger, pencil, mouse, or trackball, through which the user can provide input to the computer. Other types of devices may also be used to provide user interaction, for example, feedback provided to the user may be any form of sensory feedback, such as visual feedback, auditory feedback, or haptic feedback, and input from the user may be received in any form, including acoustic, velocity, or haptic input. FIG. 11 illustrates an example of a computing device or system according to an embodiment. The device 1100 may be a host computer connected to a network. The device 1100 may be a client computer or a server. As shown in FIG. 11, the device 1100 may be any suitable type of microprocessor-based device, such as a personal computer, a workstation, a server, or a handheld computing device (portable electronic device, e.g., a phone or tablet). The device may include, for example, one or more processors 1110, input devices 1120, output devices 1130, memory or storage devices 1140, communication devices 1160, and a nucleic acid sequencer 1170. Software 1150 resident in the memory or storage devices 1140 may include, for example, an operating system, and software for implementing the methods described herein. The input devices 1120 and output devices 1130 may generally correspond to those described herein and may be connectable to or integrated with the computer.
[0338] The input device 1120 may be any suitable device that provides input, such as a touch screen, a keyboard or keypad, a mouse, or a voice recognition device. The output device 1130 may be any suitable device that provides output, such as a touch screen, a tactile device, or a speaker.
[0339] Storage 1140 may be any suitable device that provides storage (e.g., electrical, magnetic, or optical memory, including RAM (volatile and non-volatile), cache, hard drive, or removable storage disk). Communications device 1160 may include any suitable device that can send and receive signals over a network, such as a network interface chip or device. The components of a computer may be connected in any suitable manner, for example, via wired media (e.g., a physical system bus 1180, an Ethernet connection, or any other wired transmission technology) or wirelessly (e.g., Bluetooth, Wi-Fi, or any other wireless technology).
[0340] The software modules 1150 can be stored as executable instructions in the storage 1140 and executed by the processor 1110 and can include, for example, an operating system and / or processes that embody the functionality of the methods of the present disclosure (e.g., embodied in the devices described above).
[0341] The software module 1150 may also be stored and / or transferred in any non-transitory computer-readable storage medium for use by or in connection with an instruction execution system, apparatus, or device (e.g., as described herein), which may fetch instructions associated with the software from and execute the instructions. In the context of the present disclosure, a computer-readable storage medium may be any medium, such as storage 1140, that may include or store processes for use by or in connection with an instruction execution system, apparatus, or device. Examples of computer-readable storage media may include memory units, such as hard drives, flash drives, and distribution modules, that operate as a single functional unit. Also, the various processes described herein may be embodied as modules configured to operate according to the above embodiments and techniques. Furthermore, while the processes may be shown and / or described separately, one skilled in the art will understand that the above processes may be routines or modules within other processes.
[0342] The software module 1150 may also be propagated in any transmission medium for use by or in connection with an instruction execution system, apparatus, or device such as those mentioned above, which may fetch instructions associated with the software from and execute the instructions. In the context of this disclosure, a transmission medium may be any medium that may communicate, propagate, or transmit programming for use by or in connection with an instruction execution system, apparatus, or device. Transmission-readable media may include, but are not limited to, electronic, magnetic, optical, electromagnetic, or infrared wired or wireless propagation media.
[0343] The device 1100 may be connected to a network (e.g., network 1204 shown in FIG. 12 and / or described below), which may be any suitable type of interconnected communications system. The network may implement any suitable communications protocol and may be protected by any suitable security protocol. The network may include any suitable arrangement of network links that may implement transmission and reception of network signals, such as wireless network connections (T1 or T3 lines), cable networks, DSL, or telephone lines.
[0344] The device 1100 may be implemented using any operating system, e.g., an operating system suitable for operating on a network. The software modules 1150 may be written in any suitable programming language, such as C, C++, Java, or Python. In various embodiments, application software embodying functionality of the present disclosure may be deployed in different configurations (e.g., in a client / server arrangement, or via a web browser as a web-based application or web service). In some embodiments, the operating system is executed by one or more processors, e.g., processor 1110.
[0345] The device 1100 may further include a sequencer 1170, which may be any suitable nucleic acid sequencing instrument.
[0346] 12 illustrates an example of a computing system according to one embodiment. In system 1200, device 1100 (e.g., as described above and illustrated in FIG. 11) is connected to a network 1204, which is also connected to device 1206. In some embodiments, device 1206 is a sequencer. Exemplary sequencers include, but are not limited to, Roche / 454's Genome Sequencer (GS) FLX System, Illumina / Solexa's Genome Analyzer (GA), Illumina's HiSeq 2500, HiSeq 3000, HiSeq 4000, and NovaSeq 6000 sequencing systems, Life / APG's Support Oligonucleotide Ligation Detection (SOLiD) system, Polonator's G.007 system, HeliScope Gene sequencing system from Helicos BioSciences, or Pacific Biosciences' PacBio RS system.
[0347] The devices 1100 and 1206 can communicate using a suitable communication interface over a network 1204, such as, for example, a local area network (LAN), a virtual private network (VPN), or the Internet. In some embodiments, the network 1204 can be, for example, the Internet, an intranet, a virtual private network, a cloud network, a wired network, or a wireless network. The devices 1100 and 1206 can communicate partially or entirely over wireless or wired communications, such as Ethernet, IEEE 802.11b wireless, etc. Additionally, the devices 1100 and 1206 can communicate over a second network, such as, for example, a mobile / cellular network, using a suitable communication interface. The communication between the devices 1100 and 1206 can further include or communicate with various servers, such as a mail server, a mobile server, a media server, a telephone server, etc. In some embodiments, devices 1100 and 1206 may communicate directly (instead of or in addition to communicating via network 1204), e.g., via wireless or wired communication, such as Ethernet, IEEE 802.11b wireless, etc. In some embodiments, devices 1100 and 1206 communicate via communication 1208, which may be a direct connection or may occur over a network (e.g., network 1204).
[0348] One or all of the devices 1100 and 1206 generally include logic (e.g., http web server logic) or are programmed to format data accessed from local or remote databases or other sources of data and content to provide and / or receive information over the network 1204 in accordance with various examples described herein.
[0349] Although the present disclosure and examples have been fully described with reference to the accompanying drawings, it should be noted that various modifications and changes will become apparent to those skilled in the art. Such modifications and changes should be understood to be included within the scope of the present disclosure and examples as defined by the claims. EXAMPLES
[0350] The following examples are provided to illustrate the embodiments provided and are not intended to limit the scope of the disclosure.
[0351] Example 1: Superior accuracy of the methods described herein in determining copy number alterations compared to a reference method This example illustrates a project that aims to use the methods described herein to determine copy number alterations in samples, in comparison to previous methods in the art.
[0352] In particular, this project will focus on precision or stability, i.e., how close the measurements are to each other, in estimating genome-wide loss of heterozygosity (gLOH) as a criterion for assessing the superiority of a method.
[0353] material In this example, a total of eight samples shown in Table 1 were used to evaluate gLOH scores and copy number estimation using the model of the present disclosure in comparison to some previous models. [Table 1]
[0354] Among these, samples No. 1, No. 2 and No. 4 had five different levels of tumor purity. Sample No. 3 had 20%, 25%, 30%, 40%, 50%. Sample No. 5 had 5 different levels of tumor purity. Sample No. 6 had 5 different levels of tumor purity. Samples No. 7 and No. 8 had 20%, 25%, 30%, 35%, 40%, 50%. Sample No. 8 had 1 tumor purity level.
[0355] For each tumor purity level, approximately 10-20 replicates were performed. This resulted in a total of approximately 50-100 replicates for samples No. 1, No. 2, No. 3, No. 4, No. 5, No. 6, and approximately 20 replicates for samples No. 7 and No. 8. Some variability was expected since in vitro diagnostic (IVD) assays could not be perfectly precise, but all replicated results were expected to have similar gLOH scores and CNAs since they were from the exact same samples.
[0356] result The accuracy of gLOH score estimation was compared against the models of the present disclosure, the Gibbs model (see, e.g., Sun et al. (2018), ibid.), an improved model based on grid-based selection from a family of models (see, e.g., Sun et al. (2018), ibid.; and Van Loo et al. "Allele-Specific Copy Number Analysis of Tumors", Van Loo, et al. "Allele-Specific Copy Number Analysis of Tumors", Proc Natl Acad Sci USA 2010 107(39):16910-5)), the Rookie model (an internally developed probabilistic CNA caller), the L0 model (see, e.g., Van Loo et al. (2010), ibid.), the L1 model (see, e.g., Van Loo et al. (2010), ibid.), and the L2 model (see, e.g., Van Loo et al. (2010), ibid.). (see, e.g., Van Loo, et al. (2010), ibid.) were compared between six reference models, including the LOH score estimation performance for the different models shown in Figures 13-20. The L3 and L4 models (see, e.g., Van Loo, et al. (2010), ibid.) were not included in the comparison herein because these two models did not provide CNA estimates for the majority of the replicates, especially for samples No. 2, No. 7, and No. 8.
[0357] For sample No. 1 in FIG. 13 and No. 2 in FIG. 14, the gLOH score estimates of the model described herein were more accurate than the six reference models because the model described herein had smaller variance within each target purity and more consistent gLOH score estimates across different target purities.
[0358] For sample No. 3 in FIG. 15, sample No. 4 in FIG. 16, sample No. 6 in FIG. 18, sample No. 7 in FIG. 19, and sample No. 8 in FIG. 20, the gLOH score estimation of the model described herein was as accurate as the Gibbs model and the improved model. For sample No. 5 in FIG. 17, the model described herein performed well when the purity was high, for example, 20% and 30% purity. Importantly, compared to the model described herein, all six reference models performed significantly worse when the purity was low, for example, 5% and 7%, as indicated by the estimated gLOH score of 0. Furthermore, the percent coefficient of variation (%CV) of the gLOH scores of the eight samples is summarized in Table 2 and FIG. 21. FIG. 21 shows that the %CV of the model described herein is much smaller than that of other competitors, suggesting that the gLOH score estimation of the model described herein is much more accurate than that of the six reference models. [Table 2]
[0359] For sample No. 2, the accuracy of the gLOH score estimation of the reference model was highly undesirable because the estimated gLOH scores showed too large variance across different target purities, e.g., from 20% to 50%, which was due to the unstable copy number estimates of the reference model.
[0360] A box plot was created for the average estimated copy number of bait target 3000-3500 across different target purities and models. In Figure 22, the stable gLOH scores of the models described herein are found to be due to the stable copy number estimation across different target purities. In contrast, for reference models such as Gibbs model and Rookie, whose indistinguishable modeling resulted in unstable estimated copy numbers, for example, the average copy number across bait target 3000-3500 was about 2 at target purities of 20% and 30%, but increased to 4 at target purity of 50% for the Gibbs model, ultimately resulting in an unstable gLOH score. A similar unstable pattern was seen for sample No. 1.
[0361] Finally, the computational efficiency is compared between the model described herein and the reference model, especially the Gibbs model. As shown in Table 3, the computation time for the model described herein is at least 76 times shorter (i.e., 76 times less computationally expensive or 76 times more computationally efficient) than Gibbs and Rookie, which are two methods commonly used in the field. Although the computational cost of L0, L1, and L2 is not as expensive as Gibbs and Rookie, their gLOH score estimation is shown to be highly unstable and therefore undesirable. [Table 3]
[0362] In summary, this example demonstrates the successful implementation of the present disclosure.Importantly, the method described herein shows better accuracy / stability in estimating genome-wide loss of heterozygosity (gLOH) than some reference methods in the art.Importantly, the method described herein also shows to be computationally more efficient compared to methods in the art, providing an advance over other methods for identifying copy number changes.
[0363] Example 2: Superior accuracy of the methods described herein in determining copy number alterations compared to a reference method This example illustrates another project that aims to use the methods described herein to determine copy number alterations in samples, as compared to previous methods in the art.
[0364] In particular, this project will focus on accuracy (i.e., how close the measurements are to the true value) in estimating genome-wide loss of heterozygosity (gLOH) as a criterion for assessing the superiority of a method.
[0365] material Homologous recombination deficiency (HRD) is a phenotype in which cells cannot undergo homology-mediated recombination, a process for repairing double-strand breaks. HRD is generally caused by loss of function changes in genes such as BRCA1 and BRCA2. BRCA1 and BRCA2 biallelic inactivation were defined as LOH of wild-type alleles in a sample, homozygous deletion, or mutation with two or more BRCA1 or BRCA2 changes. In this project, gLOH score accuracy was evaluated by comparing the classification performance of BRCA1 and BRCA2 biallelic inactivation between the model described herein and the improved model. Specifically, BRCA1 and BRCA2 biallelic inactivation were defined based on the estimated copy number from the improved model. A total of 21010 samples were included, with 1353 samples having ovarian cancer, 2237 samples having breast cancer, 869 samples having prostate cancer, 1421 samples having pancreatic cancer, and 15130 samples having other types of cancer.
[0366] result For each cancer type, sensitivity and specificity were calculated using a gLOH score threshold of 0.16. Table 4 shows that the sum of the sensitivity and specificity of the model described herein is greater than the sum of the sensitivity and specificity of the improved model in prostate cancer and other cancer types, and is the same for overall cancer types.
[0367] However, BRCA1 and BRCA2 biallelic inactivation were defined by the estimated copy number from the improved model.Therefore, the accuracy, i.e., sensitivity and specificity, of the improved model were overestimated.Moreover, the accuracy of the model described herein is similar to that of the improved model, even if BRCA1 and BRCA2 biallelic inactivation favors the improved model, which suggests that the model described herein is at least as accurate as the improved model. [Table 4]
[0368] In summary, this example demonstrates another successful implementation of the present disclosure.As an example, the method described herein shows superior accuracy in estimating genome-wide loss of heterozygosity (gLOH) compared to some reference methods in the art.
[0369] Exemplary Implementations Exemplary implementations of the methods and systems described herein include the following. 1. A method for determining the copy number of a target genome segment in the genome of a sample from a subject, comprising: Providing a plurality of nucleic acid molecules obtained from a sample; ligating one or more adaptors onto one or more nucleic acid molecules from the plurality of nucleic acid molecules; amplifying one or more ligated nucleic acid molecules from the plurality of nucleic acid molecules; capturing the amplified nucleic acid molecules from the amplified nucleic acid molecules; sequencing the captured nucleic acid molecule using a sequencer to obtain a plurality of sequence reads representative of the captured nucleic acid molecule, where one or more of the plurality of sequence reads overlap with a plurality of genome segments in the genome of the sample; obtaining, using one or more processors of the computer system, a plurality of sequencing depth signals for a plurality of genome segments in a genome of the sample, the sequencing depth signals being related to a number of sequence reads aligned to loci in the genome segments, the plurality of genome segments including a target genome segment; determining, using one or more processors, a first statistical moment, a second statistical moment, and a third statistical moment from the plurality of sequencing depth signals for the plurality of genome segments; determining, using the one or more processors, a tumor purity and a tumor ploidy of the sample from the first statistical moment, the second statistical moment, and the third statistical moment; determining a copy number of the target genome segment in the genome of the sample using multiple sequencing depth signals for the target genome segment, tumor purity, and tumor ploidy; generating, by the computer system, a genomic profile for the sample based on the determined copy number. 2. The method of clause 1, wherein the subject is suspected of having or determined to have cancer. 3. The method of clause 1 or clause 2, further comprising obtaining a sample from the subject. 4. The method of any one of clauses 1-3, wherein the sample comprises a tissue biopsy sample, a liquid biopsy sample, or a normal control. 5. The method of clause 4, wherein the sample is a liquid biopsy sample and comprises blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva. 6. The method of clause 4, wherein the sample is a liquid biopsy sample and comprises circulating tumor cells (CTCs). 7. The method of clause 4, wherein the sample is a liquid biopsy sample and contains cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof. 8. The method of any one of clauses 1-7, wherein the plurality of nucleic acid molecules comprises a mixture of tumor nucleic acid molecules and non-tumor nucleic acid molecules. 9. The method of clause 8, wherein the tumor nucleic acid molecule is derived from a tumor portion of a heterogeneous tissue biopsy sample and the non-tumor nucleic acid molecule is derived from a normal portion of the heterogeneous tissue biopsy sample. 10. The method of claim 8, wherein the sample comprises a liquid biopsy sample, and the tumor nucleic acid molecule is derived from a circulating tumor DNA (ctDNA) fraction of the liquid biopsy sample, and the non-tumor nucleic acid molecule is derived from a non-tumor cell-free DNA (cfDNA) fraction of the liquid biopsy sample. 11. The method of any one of clauses 1-10, wherein the one or more adaptors comprise an amplification primer, a flow cell adaptor sequence, a substrate adaptor sequence, or a sample index sequence. 12. The method of any one of clauses 1-11, wherein the captured nucleic acid molecules are captured from the amplified nucleic acid molecules by hybridization to one or more bait molecules. 13. The method of clause 12, wherein the one or more bait molecules comprise one or more nucleic acid molecules, each nucleic acid molecule comprising a region complementary to a region of a captured nucleic acid molecule. 14. The method of any one of clauses 1-13, wherein amplifying the nucleic acid molecule comprises performing a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique. 15. The method of any one of clauses 1 to 14, wherein the sequencing comprises the use of massively parallel sequencing (MPS) technology, whole genome sequencing (WGS), whole exome sequencing, targeted sequencing, direct sequencing, or Sanger sequencing technology. 16. The method of claim 15, wherein the sequencing comprises massively parallel sequencing, and the massively parallel sequencing technology comprises next generation sequencing (NGS). 17. The method of any one of clauses 1 to 16, wherein the sequencer comprises a next-generation sequencer. 18. The method of any one of clauses 1-17, further comprising generating, by the one or more processors, a report comprising the determined tumor purity, tumor ploidy, copy number of the target genome segment, genomic profile for the sample, or any combination thereof. 19. The method of claim 18, further comprising transmitting the report to a health care provider. 20. The method of claim 19, wherein the report is transmitted over a computer network or a peer-to-peer connection. 21. A method for determining the copy number of a target genome segment in the genome of a sample from a subject, comprising: obtaining, using one or more processors of the computer system, a plurality of sequencing depth signals for a plurality of genome segments in a genome of the sample, the sequencing depth signals being related to a number of sequence reads aligned to loci in the genome segments, the plurality of genome segments including a target genome segment; determining, using one or more processors, a first statistical moment, a second statistical moment, and a third statistical moment from the plurality of sequencing depth signals for the plurality of genome segments; determining, using the one or more processors, a tumor purity and a tumor ploidy of the sample from the first statistical moment, the second statistical moment, and the third statistical moment; determining a copy number of the target genome segment in the genome of the sample using multiple sequencing depth signals for the target genome segment, tumor purity, and tumor ploidy; generating, by the computer system, a genomic profile for the sample based on the determined copy number. 22. The method of claim 21, wherein the multiple sequencing depth signals of the sample are normalized using a process-matched control. 23. The method of clause 21 or clause 22, further comprising segmenting the genome to generate a plurality of genome segments. 24. The method of claim 23, wherein the genome is segmented based on multiple sequencing depth signals. 25. The method according to clause 23 or 24, wherein the genome is segmented using the circular binary segmentation (CBS) method. 26. The method of any one of clauses 21 to 25, wherein determining tumor purity and tumor ploidy comprises solving a set of nonlinear equations. 27. The method of any one of clauses 21 to 26, further comprising sequencing nucleic acid of the sample to generate sequence reads derived from the sample. 28. The method of any one of clauses 21 to 27, wherein the sequence reads derived from the sample are generated by sequencing nucleic acids of the sample using massively parallel sequencing. 29. The method of claim 28, wherein the massively parallel sequencing comprises next-generation sequencing (NGS). 30. The method of any one of clauses 21 to 29, wherein the sample is derived from an individual with lung cancer, colon cancer, ovarian cancer, breast cancer, prostate cancer, and / or pancreatic cancer. 31. The method of any one of clauses 21 to 30, wherein the target genome segment comprises a gene of interest. 32. The method of clause 31, wherein the gene of interest is the phosphatase and tensin homolog (PTEN) gene, the breast cancer 1 (BRCA1) gene, or the breast cancer 2 (BRCA2) gene. 33. The method according to clause 31, wherein the gene of interest is an oncogenic gene or a cell transforming gene. 34. The method of clause 33, wherein the oncogenic or cell transforming gene comprises an MLL fusion gene, BCR-ABL, TEL-AML I, EWS-FL11, TLS-FUS, PAX3-FKHR, Bcl-2, AML1-ETO, AML1-MTG8, Ras, Fos PDGF, RET, APC, NF-1, Rb, p53, or MDM2. 35. The method according to clause 31, wherein the gene of interest is an overexpressed gene. 36. The method according to clause 35, wherein the overexpressed gene is a multidrug resistance gene, a cyclin gene, a beta-catenin gene, a telomerase gene; c-myc, n-myc, Bel-2, Erb-B1, Erb-B2, a mutated Ras gene, a mutated Mos gene, a mutated Raf gene, or a mutated Met gene. 37. The method according to clause 31, wherein the gene of interest is a tumor suppressor gene. 38. The method of clause 37, wherein the tumor suppressor gene is p53, p21, RB1, WTI, NF1, VHL, APC, DAP kinase, p16, ARF, neurofibromin, or PTEN. 39. A method for generating a dataset comprising the copy number of a target genome segment, wherein the copy number is determined by a method according to any one of clauses 21 to 38. 40. The method of any one of clauses 21 to 39, further comprising determining a copy number alteration (CNA) of the target genome segment in the sample based on the determined copy number of the target genome segment. 41. Determining copy number alterations (CNAs) of genomic segments in a sample a) comparing the determined copy number of the target genome segment with a reference copy number of the target genome segment; b) determining a copy number alteration (CNA) from the comparison by the presence of a difference between the determined copy number and the reference copy number of the target genome segment. 42. The method according to clause 40 or clause 41, further comprising using the determined copy number alterations (CNAs) as biomarkers in medical diagnosis and / or treatment. 43. The method of any one of clauses 40 to 42, wherein the determined copy number is the copy number of the minor allele of the target genome segment. 44. The method of any one of clauses 21 to 43, further comprising determining the copy number of the minor allele of the target genome segment; and determining loss of heterozygosity (LOH) of the minor allele of the target genome segment. 45. Determining loss of heterozygosity (LOH) of the minor allele of a target genomic segment a) determining the presence of a determined copy number of a target genomic segment that is greater than 0 and less than the sum of the determined tumor ploidy and 2; b) Based on the determined existence of a); 1) a determined copy number of the target genomic segment equal to 1; 2) a determined copy number of the target genomic segment that is equal to the determined minor allele copy number of the target genomic segment; or 3) determining loss of heterozygosity (LOH) by the presence of any one of the following: a) the determined minor allele copy number of the target genomic segment is equal to 0; and b) determining loss of heterozygosity (LOH) by the presence of any one of the following: 46. The method of clause 44 or clause 45, further comprising determining a genome-wide LOH (gLOH) percentage score as the sum of the lengths of the LOH segments divided by the length of the total genome. 47. The method of any one of clauses 44 to 46, further comprising using loss of heterozygosity (LOH) as a biomarker for homologous recombination deficiency (HRD). 48. The method of any one of clauses 21 to 47, further comprising determining the tumor mutational burden (TMB) of the sample based on the determined copy number, the determined tumor purity, and / or the determined tumor ploidy. 49. Determining tumor mutation burden (TMB) a) obtaining a plurality of genetic variants from a plurality of sequencing depth signals of a sample; b) inputting the plurality of genetic variants together with the determined copy number, the determined tumor purity, and / or the determined tumor ploidy into a model configured to determine and output a plurality of genetic variants that are of somatic origin; c) determining a tumor mutation burden (TMB) of the sample by calculating the number of genetic variants of somatic origin per million base pairs of the genome based on the output of the model. 50. The method according to clause 48 or clause 49, further comprising using the determined tumor mutation burden (TMB) as a biomarker in medical diagnosis and / or treatment. 51. The method of any one of clauses 21 to 50, further comprising characterizing the mutation status of the genetic variant in the sample based on the determined copy number, the determined tumor purity, and / or the determined tumor ploidy. 52. Characterizing the mutational status of genetic variants a) obtaining genetic variants from multiple sequencing depth signals of a sample; b) obtaining a model configured to determine the mutation state of a genetic variant; and c) characterizing the mutational status of the genetic variant by inputting the genetic variant together with the determined copy number, the determined tumor purity, and / or the determined tumor ploidy into a model and outputting the mutational status of the genetic variant. 53. The method of clause 51 or clause 52, wherein the mutational status of the genetic variant is somatic or germline origin, homozygous or heterozygous state, subclonal state, or a combination thereof. 54. The method of any one of clauses 21 to 53, wherein the genomic profile of the sample is used to diagnose or confirm the diagnosis of a disease in a subject. 55. The method according to clause 54, wherein the disease is cancer. 56. The method of clause 55, further comprising selecting an anti-cancer treatment for administration to the subject based on the genomic profile of the sample. 57. The method of clause 56, further comprising determining an effective amount of an anti-cancer treatment to administer to the subject based on the genomic profile of the sample. 58. The method of clause 56 or clause 57, further comprising administering to the subject an anti-cancer treatment. 59. The method according to any one of clauses 56 to 58, wherein the anti-cancer treatment comprises chemotherapy, radiation therapy, immunotherapy, targeted therapy, or surgery. 60. Cancers include B-cell cancer (multiple myeloma), melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, endometrial cancer, oral cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, cancer of blood tissue, and glandular cancer. Cancer, Inflammatory myofibroblastoma, Gastrointestinal stromal tumor (GIST), Colon cancer, Multiple myeloma (MM), Myelodysplastic syndrome (MDS), Myeloproliferative disorder (MPD), Acute lymphocytic leukemia (ALL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), Chronic lymphocytic leukemia (CLL), Polycythemia vera, Hodgkin's lymphoma, Non-Hodgkin's lymphoma (NHL), Soft tissue sarcoma, Fibrosarcoma, Myxosarcoma, Liposarcoma, Osteosarcoma, Chordoma, Blood Angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatic carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealocytoma, hemangioblastoma 60. The method of any one of clauses 55 to 59, wherein the cancer is selected from the group consisting of bronchial tumors, acoustic neuroblastoma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, essential thrombocythemia, primary myelofibrosis, hypereosinophilic syndrome, systemic mastocytosis, familial eosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, or carcinoid tumor. 61. A method for selecting a treatment for an individual with cancer, comprising: a) determining copy number alterations (CNAs) in a sample from an individual, the CNAs being determined according to the method according to any one of clauses 40 to 43; b) using the determined CNAs as biomarkers to predict an individual's response to one or more treatment options; and c) selecting a suitable treatment for the individual from one or more treatment options based on the predicted response. 62. A method for selecting a treatment for an individual with cancer, comprising: a) determining loss of heterozygosity (LOH) in a sample from an individual, wherein LOH is determined according to a method according to any one of clauses 44 to 47; b) using the determined LOH as a biomarker to predict an individual's response to one or more treatment options; and c) selecting a suitable treatment for the individual from one or more treatment options based on the predicted response. 63. A method for selecting a treatment for an individual with cancer, comprising: Determining the tumor mutation burden (TMB) in a sample from the individual, wherein the TMB is determined according to the method of any one of clauses 48 to 50; Using the determined TMB as a biomarker to predict an individual's response to one or more treatment options. and selecting an appropriate treatment for the individual from one or more treatment options based on the predicted response. 64. A method for selecting a treatment for an individual with cancer, comprising: characterizing the mutation status of a genetic variant in a sample from an individual, wherein the mutation status is characterized according to a method according to any one of clauses 51 to 53; predicting the individual's response to one or more treatment options based on the characterized mutation status of the genetic variant; and selecting an appropriate treatment for the individual from one or more treatment options based on the predicted response. 65. The method according to clause 64, wherein the mutational status of the genetic variant is the origin of the genetic variant, which is somatic or germline. 66. The method of any one of clauses 61 to 65, further comprising administering a selected treatment to the individual. 67. Cancers include B-cell cancer (multiple myeloma), melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, endometrial cancer, oral cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, cancer of blood tissue, and glandular cancer. Cancer, Inflammatory myofibroblastoma, Gastrointestinal stromal tumor (GIST), Colon cancer, Multiple myeloma (MM), Myelodysplastic syndrome (MDS), Myeloproliferative disorder (MPD), Acute lymphocytic leukemia (ALL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), Chronic lymphocytic leukemia (CLL), Polycythemia vera, Hodgkin's lymphoma, Non-Hodgkin's lymphoma (NHL), Soft tissue sarcoma, Fibrosarcoma, Myxosarcoma, Liposarcoma, Osteosarcoma, Chordoma, Blood Angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatic carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealocytoma, hemangioblastoma 67. The method of any one of clauses 61 to 66, wherein the cancer is selected from the group consisting of bronchial tumors, acoustic neuroblastoma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, essential thrombocythemia, primary myelofibrosis, hypereosinophilic syndrome, systemic mastocytosis, familial eosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, and carcinoid tumors. 68. The method of any one of clauses 61 to 67, wherein the sample comprises a tissue biopsy sample, a liquid biopsy sample, or a normal control. 69. The method according to clause 68, wherein the sample is a liquid biopsy sample and comprises blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva. 70. The method of claim 68, wherein the sample is a liquid biopsy sample and contains circulating tumor cells (CTCs). 71. The method of clause 68, wherein the sample is a liquid biopsy sample and contains cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof. 72. The method according to any one of clauses 61 to 71, wherein the selected treatment comprises drug administration, chemotherapy, radiation therapy, immunotherapy, targeted therapy, gene therapy, surgery, or any combination thereof. 73. The method of any one of clauses 61-72, wherein the selected treatment comprises administering a checkpoint inhibitor to the individual. 74. The method of any one of clauses 61 to 73, further comprising generating or updating a report from the method of selecting a treatment. 75. The method of claim 74, further comprising transmitting the report to the individual or to a clinician. 76. The method of clause 74 or clause 75, further comprising storing the report in a non-transitory computer-readable storage medium. 77. The method of any one of clauses 74-76, further comprising displaying the report on a computer display. 78. A non-transitory computer-readable storage medium containing one or more programs executed by one or more processors of a device, the one or more programs containing instructions that, when executed by the one or more processors, cause the device to perform a method according to any one of clauses 1 to 77. 79. A non-transitory computer-readable storage medium comprising a report generated from performing a method according to any one of clauses 21-77. 80. An electronic device (or system) comprising one or more processors and a memory communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the electronic device (or system) to perform a method according to any one of clauses 1 to 77. 81. The electronic device (or system) of clause 79, further comprising one or more displays for presenting a report generated from carrying out the method of any one of clauses 21 to 77.
[0370] From the foregoing, it should be understood that, although specific embodiments of the disclosed method and system have been illustrated and described, various modifications can be made thereto and are contemplated herein. It is also not intended that the present invention be limited by the specific examples provided herein. Although the present invention has been described with reference to the above specification, the description and illustration of the preferred embodiments herein are not meant to be construed in a limiting sense. Furthermore, it should be understood that all aspects of the present invention are not limited to the specific depictions, configurations, or relative proportions set forth herein, which depend upon various conditions and variables. Various modifications in form and details of the embodiments of the present invention will be apparent to those skilled in the art. Thus, the present invention is also intended to encompass any such modifications, variations, and equivalents.
Claims
1. 1. A method for determining the copy number of a target genome segment in a genome of a sample from a subject, comprising: obtaining, using one or more processors of a computer system, a plurality of sequencing depth signals for a plurality of genome segments in the genome of the sample, wherein the sequencing depth signals are associated with a number of sequence reads aligned to loci in the genome segments, the plurality of genome segments including a target genome segment; determining, using the one or more processors, a first statistical moment, a second statistical moment, and a third statistical moment from the plurality of sequencing depth signals for the plurality of genome segments; determining, using the one or more processors, a tumor purity and a tumor ploidy of the sample from the first statistical moment, the second statistical moment, and the third statistical moment; determining the copy number of the target genome segment in the genome of the sample using a plurality of sequencing depth signals for the target genome segment, the tumor purity, and the tumor ploidy; generating, by the computer system, a genomic profile for the sample based on the determined copy number.
2. 2. The method of claim 1, wherein the multiple sequencing depth signals of the sample are normalized using a process matched control.
3. 2. The method of claim 1, further comprising segmenting the genome to generate the plurality of genome segments.
4. The method of claim 3, wherein the genome is segmented based on the multiple sequencing depth signals.
5. 4. The method of claim 3, wherein the genome is segmented using a circular binary segmentation (CBS) method.
6. 10. The method of claim 1, wherein determining the tumor purity and the tumor ploidy comprises solving a set of nonlinear equations.
7. 2. The method of claim 1, wherein the sample is from an individual with lung cancer, colon cancer, ovarian cancer, breast cancer, prostate cancer, and / or pancreatic cancer.
8. 10. The method of claim 1, wherein the target genome segment comprises a gene of interest.
9. 9. The method of claim 8, wherein the gene of interest is the phosphatase and tensin homolog (PTEN) gene, the breast cancer 1 (BRCA1) gene, or the breast cancer 2 (BRCA2) gene.
10. The method of claim 8, wherein the gene of interest is an oncogenic gene or a cell transforming gene.
11. 11. The method of claim 10, wherein the oncogenic or cell transforming gene comprises an MLL fusion gene, BCR-ABL, TEL-AML I, EWS-FL11, TLS-FUS, PAX3-FKHR, Bcl-2, AML1-ETO, AML1-MTG8, Ras, Fos PDGF, RET, APC, NF-1, Rb, p53, or MDM2.
12. The method of claim 8, wherein the gene of interest is an overexpressed gene.
13. 13. The method of claim 12, wherein the overexpressed gene is a multidrug resistance gene, a cyclin gene, a beta-catenin gene, a telomerase gene; c-myc, n-myc, Bel-2, Erb-B1, Erb-B2, a mutated Ras gene, a mutated Mos gene, a mutated Raf gene, or a mutated Met gene.
14. The method of claim 8 , wherein the gene of interest is a tumor suppressor gene.
15. 15. The method of claim 14, wherein the tumor suppressor gene is p53, p21, RB1, WTI, NF1, VHL, APC, DAP kinase, p16, ARF, neurofibromin, or PTEN.
16. 13. A method for generating a dataset comprising copy numbers of a target genome segment, wherein the copy numbers are determined by the method of claim 1.
17. 2. The method of claim 1, further comprising determining a copy number alteration (CNA) of the target genome segment in the sample based on the determined copy number of the target genome segment.
18. Determining the copy number alterations (CNAs) of the genomic segments in the sample includes: a) comparing the determined copy number of the target genome segment with a reference copy number of the target genome segment; b) determining the copy number alteration (CNA) from the comparison by the presence of a difference between the determined copy number and the reference copy number of the target genome segment.
19. The method of claim 17, further comprising using the determined copy number alterations (CNAs) as biomarkers in medical diagnosis and / or treatment.
20. 18. The method of claim 17, wherein the determined copy number is the copy number of a minor allele of the target genome segment.
21. 2. The method of claim 1, further comprising determining a copy number of a minor allele of the target genome segment; and determining loss of heterozygosity (LOH) of the minor allele of the target genome segment.
22. Determining the loss of heterozygosity (LOH) of the minor allele of the target genomic segment includes: a) determining the presence of the determined copy number of the target genome segment that is greater than 0 and less than the sum of the determined tumor ploidy and 2; b) based on said determined presence of a), 1) the determined copy number of the target genome segment is equal to 1; 2) the determined copy number of the target genome segment equal to the determined minor allele copy number of the target genome segment; or 3) determining the loss of heterozygosity (LOH) by the presence of any one of the determined minor allele copy numbers of the target genome segment being equal to 0.
23. 22. The method of claim 21, further comprising determining a genome-wide LOH (gLOH) percentage score as the sum of the lengths of the LOH segments divided by the length of the entire genome.
24. 22. The method of claim 21, further comprising using said loss of heterozygosity (LOH) as a biomarker for homologous recombination deficiency (HRD).
25. 2. The method of claim 1, further comprising determining a tumor mutational burden (TMB) of the sample based on the determined copy number, the determined tumor purity, and / or the determined tumor ploidy.
26. Determining the tumor mutational burden (TMB) comprises: a) obtaining a plurality of genetic variants from the plurality of sequencing depth signals of the sample; b) inputting the plurality of genetic variants together with the determined copy number, the determined tumor purity, and / or the determined tumor ploidy into a model configured to determine and output a plurality of genetic variants that are of somatic origin; and c) determining the tumor mutational burden (TMB) of the sample by calculating the number of genetic variants of somatic origin per million base pairs of the genome based on the output of the model.
27. 26. The method of claim 25, further comprising using the determined tumor mutation burden (TMB) as a biomarker in medical diagnosis and / or treatment.
28. 2. The method of claim 1, further comprising characterizing a mutational status of genetic variants in the sample based on the determined copy number, the determined tumor purity, and / or the determined tumor ploidy.
29. Characterizing the mutation status of the genetic variant may include: a) obtaining genetic variants from the plurality of sequencing depth signals of the sample; b) obtaining a model configured to determine the mutational state of a genetic variant; and c) characterizing the mutational status of the genetic variant by inputting the genetic variant together with the determined copy number, the determined tumor purity, and / or the determined tumor ploidy into the model and outputting the mutational status of the genetic variant.
30. 29. The method of claim 28, wherein the mutational state of the genetic variant is somatic or germline origin, homozygous or heterozygous state, subclonal state, or a combination thereof.
31. 10. The method of claim 1, wherein the genomic profile of the sample is used to diagnose or confirm a diagnosis of a disease in the subject.
32. 32. The method of claim 31 , wherein the disease is cancer.
33. 33. The method of claim 32, further comprising selecting an anti-cancer treatment for administration to the subject based on the genomic profile of the sample.
34. 34. The method of claim 33, further comprising determining an effective amount of an anti-cancer therapy to administer to the subject based on the genomic profile of the sample.
35. 34. The method of claim 33, further comprising administering the anti-cancer treatment to the subject.
36. 34. The method of claim 33, wherein the anti-cancer treatment comprises chemotherapy, radiation therapy, immunotherapy, targeted therapy, or surgery.
37. 1. A method for selecting a treatment for an individual having cancer, the method comprising: a) determining copy number alterations (CNAs) in a sample from said individual, said CNAs being determined according to the method of claim 17; b) using said determined CNAs as biomarkers to predict said individual's response to one or more treatment options; and c) selecting a suitable treatment for the individual from said one or more treatment options based on said predicted response.
38. 1. A method for selecting a treatment for an individual having cancer, the method comprising: a) determining loss of heterozygosity (LOH) in a sample from said individual, said LOH being determined according to the method of claim 21; b) using the determined LOH as a biomarker to predict the individual's response to one or more treatment options; and c) selecting a suitable treatment for the individual from said one or more treatment options based on said predicted response.
39. 1. A method for selecting a treatment for an individual having cancer, the method comprising: a) determining a tumor mutational burden (TMB) in a sample from the individual, wherein the TMB is determined according to the method of claim 25; b) using the determined TMB as a biomarker to predict the individual's response to one or more treatment options; and c) selecting a suitable treatment for the individual from said one or more treatment options based on said predicted response.
40. 1. A method for selecting a treatment for an individual having cancer, the method comprising: a) characterizing a mutation status of a genetic variant in a sample from the individual, wherein the mutation status is characterized according to the method of claim 28; b) predicting the individual's response to one or more treatment options based on the characterized mutation status of the genetic variant; and and c) selecting a suitable treatment for the individual from said one or more treatment options based on said predicted response.
41. 41. The method of claim 40, wherein the mutational status of the genetic variant is the origin of the genetic variant, which is somatic or germline.
42. 38. The method of claim 37, further comprising administering the selected treatment to the individual.
43. 38. The method of claim 37, wherein the sample comprises a tissue biopsy sample, a liquid biopsy sample, or a normal control.
44. 44. The method of claim 43, wherein the sample is a liquid biopsy sample and comprises blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva.
45. 44. The method of claim 43, wherein the sample is a liquid biopsy sample and comprises circulating tumor cells (CTCs).
46. 44. The method of claim 43, wherein the sample is a liquid biopsy sample and comprises cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof.
47. 38. The method of claim 37, wherein the selected treatment comprises drug administration, chemotherapy, radiation therapy, immunotherapy, targeted therapy, gene therapy, surgery, or any combination thereof.
48. 38. The method of claim 37, wherein the selected treatment comprises administering a checkpoint inhibitor to the individual.
49. 13. A non-transitory computer-readable storage medium comprising one or more programs for execution by one or more processors of a device, the one or more programs comprising instructions that, when executed by the one or more processors, cause the device to perform the method of claim 1.
50. 11. A system comprising: one or more processors; and a memory communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the device to perform the method of claim 1.
